Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Linda S. Steelman1,2, William H. Chappell1, Stephen L. Abrams1, C. Ruth Kempf2, Jacquelyn Long2, Piotr Laidler3, Sanja Mijatovic4, Danijela Maksimovic-Ivanic4, Franca Stivala5, Maria C. Mazzarino5, Marco Donia5, Paolo Fagone5, Graziella Malaponte5, Ferdinando Nicoletti5, Massimo Libra5, Michele Milella6, Agostino Tafari7, Antonio Bonati8, Jörg Bäsecke9, Lucio Cocco10, Camilla Evangelisti10, Alberto M. Martelli10,11, Giuseppe Montalto12, Melchiorre Cervello13 and James A. McCubrey1

1Department of Microbiology and Immunology, 2Department of Physics, East Carolina University, Greenville, NC 27858, USA
3Department of Medical Biochemistry, Jagiellonian University Medical College, Krakow, Poland
4Department of Immunology, Institute of Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
5Department of Biomedical Sciences, University of Catania, Catania, Italy
6Regina Elena Cancer Center, Rome 00144, Italy
7University of Rome, La Sapienza, Department of Hematology-Oncology, Rome 99161, Italy
8University Hospital of Parma, Unit of Hematology and Bone-Marrow Transplantation, Via Gramsi n.14, Parma 43100, Italy
9Department of Medicine, University of Göttingen, Göttingen, Germany
10Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell’Apparato Locomotore, Università di Bologna, Bologna, Italy
11IGM-CNR, Sezione di Bologna, C/o IOR, Bologna, Italy
12Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy
13Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia, Molecolare"Alberto Monroy", Palermo, Italy

Key words: Raf, MEK, PI3K, mTOR, cancer, kinases, protein phosphorylation, signal transduction, apoptosis

Received: 2/25/11; Accepted: 3/10/11; Published: 3/10/11

Corresponding author: James A. McCubrey, PhD; Email: mccubreyj@ecu.edu

© Steelman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract: Dysregulated signaling through the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways is often the result of genetic alterations in critical components in these pathways or upstream activators. Unrestricted cellular proliferation and decreased sensitivity to apoptotic-inducing agents are typically associated with activation of these pro-survival pathways. This review discusses the functions these pathways have in normal and neoplastic tissue growth and how they contribute to resistance to apoptotic stimuli. Crosstalk and commonly identified mutations that occur within these pathways that contribute to abnormal activation and cancer growth will also be addressed. Finally the recently described roles of these pathways in cancer stem cells, cellular senescence and aging will be evaluated. Controlling the expression of these pathways could ameliorate human health.
INTRODUCTION

The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR signaling pathways have been shown over the past 25 years to play key roles in the transmission of proliferative signals from membrane bound receptors. Mutations can occur in the genes encoding pathway constituents (e.g., *RAS*, *RAF*, *PIK3CA*, *PTEN*, *AKT*, *TSC1*, *TSC2*) or in upstream receptors which activate these pathways. These pathways relay this information through interactions with various other proteins to the nucleus to control gene expression [1-13]. This review will discuss how these pathways may be aberrantly regulated by either upstream mutations/amplification or by intrinsic mutations of key components of these signaling pathways. Elevated levels of activated components of these pathways are often associated with poor prognosis in cancer patients or premature aging [2-5, 7]. Increased expression of signaling pathways can also be correlated with altered sensitivity to targeted therapy compared to patients that do not exhibit elevated expression [2-4]. Inhibition of Raf, MEK, PI3K, Akt and mTOR may prove useful in cancer treatment as well as in preventing or suppressing cellular aging. These observations have propelled the pharmaceutical industry to develop inhibitors that target key components of these pathways.

The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR signaling pathways consist of kinases cascades that are regulated by phosphorylation and de-phosphorylation by specific kinases, phosphatases as well as GTP/GDP exchange proteins, adaptor proteins and scaffolding proteins. The regulation of these cascades can be much like the axiom of real estate, “location-location-location”, as the membrane localization of these components is often critical for their activity, even though some members of these pathways can function in other cellular regions (e.g., mitochondrion, nucleus). Indeed, one emerging observation in both extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mammalian target of rapamycin (mTOR) signaling is the realization that pathways generate specific biological responses dependent upon where in the cell the signal originates [12]. For example, phosphorylation of both epidermal growth factor receptor (EGFR) and cytosolic phospholipase A2 (cPLA2) is most prominent when ERK1/2 is activated from lipid rafts, whereas p90 Ribosomal S6 kinase-1 (p90Rsk1) is mainly activated by Ras signals emanating from disordered membranes. This substrate selectivity is governed by the participation of different scaffold proteins that distinctively couple ERK1/2, activated at defined subcellular domains, to specific substrates. Ras subcellular localization can determine substrate specificity through distinct utilization of scaffold proteins [1,6,12]. Clearly the subcellular localization of pathway components and the presence of various adaptor and scaffolding molecules are critical for the activity of these pathways. The regulation and function of these two pathways will be concisely reviewed as well as the effects of genetic mutations that are important in human cancer.

The Ras/Raf/MEK/ERK Pathway

An introductory overview of the Ras/Raf/MEK/ERK pathway is presented in Figure 1. Also outlined in this figure are common sites of intervention with signal transduction inhibitors. Many of these inhibitors have been evaluated in various clinical trials and some are currently being used to treat patients with specific cancers. Extensive reviews of many inhibitors targeting these pathways have been recently published [2-4]. This figure serves as a starting reference point for understanding the flow of information through the Ras/Raf/MEK/ERK pathway from a growth factor to a specific receptor to phosphorylation of appropriate transcription factors in the nucleus, which modulate the expression of key genes [7-11]. The effects of this pathway on the translational apparatus are also diagrammed. Often mRNAs encoding growth factors are entitled “weak” mRNAs and require the effects of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways for efficient translation [4,11]. As an example, we present the autocrine production of a growth factor. Importantly, many components and interacting members of this pathway are also present as mutated forms in the genomes of retroviruses that induced cancer in experimental animals. Thus there have always been direct pivotal links of this pathway with malignancy.

After growth factor/cytokine/mitogen stimulation of the appropriate (cognate) receptor, a Src homology 2 domain containing protein (Shc) adaptor protein becomes associated with the C-terminus of the specific activated growth factor receptor (e.g., vascular endothelial growth factor receptor [VEGFR], epidermal growth factor receptor [EGFR], insulin like growth factor-1 receptor [IGF-1R] and many others) [2-4]. She recruits the Grb2 protein and the Son of sevenless (SOS) homolog protein, resulting in the loading of membrane-bound Ras with GTP [7]. Ras can also be activated by growth factor receptor tyrosine kinases [GFRTK], such as insulin receptor (IR), via intermediates like insulin receptor substrate (IRS) proteins that bind growth factor receptor-bound protein 2 [7,8]. Ras:GTP then recruits Raf to the membrane where it becomes activated, likely via a Src-family tyrosine (Y) kinase [9]. At this point
we will be somewhat generic, although it should be pointed out that both Ras and Raf are members of multi-gene families and there are three Ras members (Ki-Ras, N-Ras and Ha-Ras) [7] and three Raf members (B-Raf, Raf-1 [a.k.a c-Raf] and A-Raf) [9]. Raf is responsible for serine/threonine (S/T) phosphorylation of mitogen-activated protein kinase kinase-1 (MEK1) [2,3,7]. MEK1 phosphorlates ERK1 and 2 at specific T and Y residues [10]. Activated ERK1 and ERK2 serine S/T kinases phosphorylate and activate a variety of substrates, including p90Rsk1 [2,3,7,10]. ERK1/2 has many downstream and even upstream substrates (see below). p90Rsk1 can activate the cAMP response element binding protein (CREB) transcription factor [13].

The number of ERK1/2 targets is easily in the hundreds (>600). Thus suppression of MEK and ERK activities will have profound effects on cell growth and aging. Activated ERK can also phosphorylate B-Raf, Raf-1 and MEK1 which alter their activity (Figure 1). Depending upon the site phosphorylated on Raf-1, ERK phosphorylation can either enhance [14] or inhibit [15] Raf-1 activity. In contrast, when B-Raf [16] or MEK1 [17] are phosphorylated by ERK, their activity decreases. These phosphorylation events serve to alter the stability and/or activities of the proteins. This is the first discussion of feed-back loops which will become important in consideration of whether to just target MEK or to target both Raf and MEK in various cancers. It is important that the reader realize that certain phosphorylation events can either inhibit or repress the activity of the affected protein. This often depends on the particular residue phosphorylated on the protein which can confer a different configuration to the protein or target the protein to a different subcellular localization that may result in proteosomal degradation. Furthermore, as previously mentioned, certain phosphorylation events will actually serve to shut off or slow down the pathway. Thus protein phosphorylation by the Ras/Raf/MEK/ERK pathway is a very intricate process which serves to fine tune the signal often originating from a growth factor or mitogens.

Activated ERK can translocate to the nucleus and phosphorylate additional transcription factors, such as Elk-1, CREB, Fos and globin transcription factor l (Gata-1) and others [2-4, 14,18], that bind promoters of many genes, including growth factor and cytokine genes that are important in promoting growth and preventing apoptosis of multiple cell types. Under certain circumstances, aberrant regulation of this pathway can contribute to abnormal cellular proliferation which may lead to many abnormalities including: autocrine transformation, drug resistance, senescence or premature aging [2,4,5,19].

The Ras/PI3K/PTEN/Akt/mTOR Pathway

An introductory overview of the Ras/PI3K/PTEN/Akt/mTOR pathway is presented in Figure 2. Also outlined in this diagram are common sites of intervention with signal transduction inhibitors. Many of these inhibitors have been evaluated in various clinical trials and some are currently being used to treat patients with specific cancers. Extensive reviews of many inhibitors targeting these pathways have been recently published [2,4,19,20]. Phosphatidylinositol-3-kinase (PI3K) is a heterodimeric protein with an 85-kDa regulatory subunit and a 110-kDa catalytic subunit (PIK3CA) [20,21]. PI3K serves to phosphorylate a series of membrane phospholipids including phosphatidylinositol 4-phosphate (PtdIns(4)P) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), catalyzing the transfer of ATP-derived phosphate to the D-3 position of the inositol ring of membrane phosphoinositides, thereby forming the second messenger lipids phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) [4,19,20]. Most often, PI3K is activated via the binding of a ligand to its cognate receptor, whereby p85 associates with phosphorylated tyrosine residues on the receptor via a Src-homology 2 (SH2) domain. After association with the receptor, the p110 catalytic subunit then transfers phosphate groups to the aforementioned membrane phospholipids [4,19,20]. It is these lipids, specifically PtdIns(3,4,5)P3, that attract a series of kinases to the plasma membrane thereby initiating the signaling cascade [4,19,20].

Downstream of PI3K is the primary effector molecule of the PI3K signaling cascade, Akt/protein kinase B (PKB). Akt was originally discovered as the cellular homologue of the transforming retrovirus AKT8 and as a kinase with properties similar to protein kinases A and C [4,19,21,22]. Akt contains an amino-terminal pleckstrin homology (PH) domain that serves to target the protein to the membrane for activation [21,22]. Within its central region, Akt has a large kinase domain and is flanked on the carboxy-terminus by hydrophobic and proline-rich regions [22]. Akt is activated via phosphorylation of two residues: T308 and S473.

The phosphotidylinositol-dependent kinases (PDKs) are responsible for activation of Akt. PDK1 is the kinase responsible for phosphorylation of T308 [23]. Akt is also phosphorylated by the mammalian target of Rapamycin (mTOR) complex referred to as (Rapamycin-insensitive companion of mTOR/mLST8 complex) mTORC2 [4,19] (See Figures 2 & 3). Before its discovery, the activity responsible for this
Figure 1. Overview of the Ras/Raf/MEK/ERK Pathway and Potential Sites of Therapeutic Intervention with Small Molecule Membrane-Permeable Inhibitors. The Ras/Raf/MEK/ERK pathway is regulated by Ras (indicated in green ovals), as well as various upstream growth factor receptors (indicated in purple) and non-receptor kinases. Sites where various small molecule inhibitors suppress this pathway are indicated by red octagons. The downstream transcription factors regulated by this pathway are indicated in purple diamond shaped outlines. The Ras/Raf/MEK/ERK pathway also interacts with key proteins involved in protein translation (indicated in green ovals). The Ras/Raf/MEK/ERK pathway aids in the assembly of the protein translation complex responsible for the translation of “weak” mRNAs (indicated in a red line folding over on itself) important in the prevention of apoptosis. This drawing depicts a relative common, yet frequently overlooked phenomenon in human cancer, autocrine transformation. GF = growth factor, GFR = growth factor receptor.
Figure 2. Overview of the Ras/PI3K/PTEN/Akt/mTOR Pathway and Potential Sites of Therapeutic Intervention. The Ras/PI3K/PTEN/mTOR pathway is regulated by Ras (indicted in green ovals), as well as various upstream growth factor receptors (indicated in purple). Sites where various small molecule inhibitors suppress this pathway are indicated by red octagons. Naturally occurring miRNAs have been discovered to certain components of this pathway (e.g., PTEN) and are indicated in a red triangle; other miRNAs to other components, especially tumor suppressor genes will likely be discovered. The downstream transcription factors regulated by this pathway are indicated in diamond shaped purple (active) or red (inactivated) outlines. This drawing depicts some of the complicated regulations of this pathway by both positive and negative phosphorylation events which serve to fine tune this pathway. Phosphorylation of some molecules by certain kinases (e.g., phosphorylation of β-catenin by glycogen synthase kinase-3β [GSK-3β], indicated in red oval) results in their proteosomal degradation (indicated in red box), while phosphorylation of some molecules by certain kinases (e.g., β-catenin by Akt) results in their activation (nuclear translocation, indicated in green box). The Ras/PI3K/PTEN/Akt/mTOR pathway plays a key role in regulating p53 activity (indicated in purple diamond) by phosphorylating MDM2 (indicated in red oval) which controls the stability of p53 by ubiquitination. The Ras/PI3K/PTEN/Akt/mTOR pathway plays a key role in regulating critical proteins involved in protein translation (indicated in green ovals), especially those necessary for the translation of “weak” mRNAs (mTORC1, grouped together a purple box). This pathway also indicates that Akt can result in the activation of downstream mTOR which can subsequently serve as either a negative feed back to inactivate Akt by p70S6K or activate Akt by mTORC2 (grouped together in a blue box). GF = growth factor, GFR = growth factor receptor.
phosphorylation event was referred to as PDK2. Therefore, phosphorylation of Akt is somewhat complicated as it is phosphorylated by a complex that lies downstream of activated Akt itself [4,19]. Thus, as with the Ras/Raf/MEK/ERK pathway, there are feedback loops that serve to regulate the Ras/PI3K/PTEN/Akt/mTOR pathway. Once activated, Akt leaves the cell membrane to phosphorylate intracellular substrates.

After activation, Akt is able to translocate to the nucleus [4,19,24] where it affects the activity of a number of transcriptional regulators. CREB [25], E2F [26], nuclear factor-κappa B cells (NF-κB) via inhibitor κappa B protein kinase (Ik-K) [27], the forkhead transcription factors [28] and murine double minute 2 (MDM2) which regulates p53 activity. These are all either direct or indirect substrates of Akt and each can regulate cellular proliferation, survival and epithelial mesenchymal transition (EMT) [4,11,19,28-31]. Aside from transcription factors, Akt is able to target a number of other molecules to affect the survival state of the cell including: the pro-apoptotic molecule Bel-2-associated death promoter (BAD) [29], and glycogen-synthase kinase-3β (GSK-3β) [30]. GSK-3β regulates β-catenin protein stability. Hence the PI3K/PTEN/Akt/mTOR pathway is connected to the Wnt/β-catenin, p53 and many additional pathways (Figure 3).

Negative regulation of the PI3K pathway is primarily accomplished through the action of the phosphatase and tensin homologue deleted on chromosome ten (PTEN) tumor suppressor proteins. PTEN encodes a lipid and protein phosphatase whose primary lipid substrate is PtdIns(3,4,5)P3 [31-39]. The purported protein substrate(s) of PTEN are more varied, including focal adhesion kinase (FAK), the Shc exchange protein and the transcriptional regulators ETS-2 and Sp1 and the platelet-derived growth factor receptor (PDGFR) [31-33].

PTEN has four primary structural domains. On the amino terminus is the lipid and protein phosphatase domain, which is flanked adjacent to the C2 domain that is responsible for lipid binding and membrane localization. Next are two protein sequences rich in proline (P), glutamic acid (E), serine (S), and threonine (T) (PEST) domains that regulate protein stability. Lastly, PTEN has a PDZ domain, which helps facilitate protein-protein interactions. Mutations within the phosphatase domain have been reported to nullify the endogenous function of PTEN [31, 35]. Thus PTEN is an enticing therapeutic target for activation since it is frequently inactivated in many human cancers through point mutations as well as other means (e.g., promoter hypermethylation, gene deletion) and its inactivation results in elevated Akt activity and abnormal growth regulation [31, 35]. Moreover, PTEN can be inactivated by phosphorylation and oxidation in human cancer and which results in elevated Akt activity and abnormal growth regulation [31,35,36]. Thus, drugs reactivating PTEN could potentially be very useful in some types of tumors driven by PTEN inactivation.

Another negative regulator of the PI3K pathway is the PH domain leucine-rich repeat protein phosphatase (PHLPP). PHLPP dephosphorylates 5473 on Akt which induces apoptosis and inhibits tumor growth [37]. Two other phosphatases, SH2 domain-containing inositol 5′phosphatase (SHIP)-1 and SHIP-2, remove the 5′-phosphate from PtdIns(3,4,5)P3 to produce PtdIns(3,4)P2 [38-41]. Mutations in these phosphatases, which eliminate their activity, can lead to tumor progression. Consequently, the genes encoding these phosphatases are referred to as anti-oncogenes or tumor suppressor genes.

Next we discuss some of the key downstream targets of Akt that can also contribute to abnormal cellular growth and are key therapeutic targets [4,19,35,42-47]. Akt-mediated regulation of mTOR activity is a complex multi-step phenomenon. Some of these targets and how they interact with the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways are indicated in Figure 3. Akt inhibits tuberous sclerosis 2 (TSC2 or hamartin) function through direct phosphorylation [4,19,35,42]. TSC2 is a GTPase-activating protein (GAP) that functions in association with the putative tuberous sclerosis 1 (TSC1 or tuberin) to inactivate the small G protein Rheb [4,19,35,43,44]. TSC2 phosphorylation by Akt represses GAP activity of the TSC1/TSC2 complex, allowing Rheb to accumulate in a GTP-bound state. Rheb-GTP then activates, through a mechanism not yet fully elucidated, the protein kinase activity of mTOR when complexes with the Raptor (Regulatory associated protein of mTOR) adaptor protein, DEPTOR and mLST8, a member of the Lethal-with-Sec-Thirteen gene family, first identified in yeast [4,19]. The mTOR/Raptor/mLST8 complex (mTORC1) is sensitive to rapamycin and, importantly, inhibits Akt via a negative feedback loop which involves, at least in part, p70S6K [44]. This is due to the negative effects that p70S6K has on IRS1 [43] (see Figure 3).

The mechanism by which Rheb-GTP activates mTORC1 has not been fully elucidated yet, however it requires Rheb farnesylation and can be blocked by farnesyl transferase (FT) inhibitors. It has been proposed that Rheb-GTP would relieve the inhibitory function of FKB38 (another component of mTORC1)
on mTOR, thus leading to mTORC1 activation [44]. However, more recent investigations did not confirm these findings [45].

Nevertheless, Akt also phosphorylates proline-rich Akt-substrate-40 (PRAS40), an inhibitor of mTORC1, and by doing so, it prevents the ability of PRAS40 to suppress mTORC1 signalling (recently reviewed in [4,19,44]). Thus, this could be yet another mechanism by which Akt activates mTORC1. Moreover, PRAS40 is a substrate of mTORC1 itself, and it has been demonstrated that mTORC1-mediated phosphorylation of PRAS40 facilitates the removal of its inhibition on downstream signaling of mTORC1 [4,19,44]. Also Ras/Raf/MEK/ERK signaling positively impinges on mTORC1. Indeed, both p90Rsk-1 and ERK 1/2 phosphorylate TSC2, thus suppressing its inhibitory function [4,19,44] (See Figure 3). Moreover, recent evidence has highlighted that, in solid tumors, mTORC1 inhibition resulted in ERK 1/2 activation, through p70S6K/PI3K/Ras/Raf/MEK [46].

The relationship between Akt and mTOR is further complicated by the existence of the mTOR/Rictor complex (mTORC2), which, in some cell types, displays rapamycin-insensitive activity. mTORC2 has been found to directly phosphorylate Akt on S473 in vitro and to facilitate T308 phosphorylation. Thus, mTORC2 can function as the elusive PDK-2 which phosphorylates Akt on S473 in response to growth factor stimulation [47]. Akt and mTOR are linked to each other via positive and negative regulatory circuits, which restrain their simultaneous hyperactivation through a mechanism involving p70S6K and PI3K [4,19,35,44,48-55]. Assuming that equilibrium exists between these two complexes, when the mTORC1 complex is formed, it could antagonize the formation of the mTORC2 complex and reduce Akt activity [44-46]. Thus, at least in principle, inhibition of the mTORC1 complex could result in Akt hyperactivation. This is one problem associated with therapeutic approaches using rapamycin that block some actions of mTOR but not all.

mTOR is a 289-kDa S/T kinase. It regulates translation in response to nutrients and growth factors by phosphorylating components of the protein synthesis machinery, including p70S6K and eukaryotic initiation factor (eIF)-4E binding protein-1 (4EBP-1), the latter resulting in release of the eukaryotic initiation factor-4E eIF-4E, allowing eIF-4E to participate in the assembly of a translational initiation complex [4,19,35,44]. p70S6K phosphorylates the 40S ribosomal protein S6, (rps6), leading to active translation of mRNAs [4,19,35,44]. Integration of a variety of signals (mitogens, growth factors, hormones) by mTOR assures cell cycle entry only if nutrients and energy are sufficient for cell duplication [4,48-52]. Therefore, mTOR controls multiple steps involved in protein synthesis, but importantly enhances production of key molecules such as c-Myc, cyclin D1, p27Kip1, and retinoblastoma protein (pRb) [35].

mTOR also controls the translation of hypoxia-inducible transcription factor-1α (HIF-1α) mRNA [51,52]. HIF-1α upregulation leads to increased expression of angiogenic factors such as vascular endothelial growth factor (VEGF) and PDGF [4]. Moreover, HIF-1α regulates the glycolytic pathway by controlling the expression of glucose-sensing molecules including glucose transporter (Glut) 1 and Glut3 [51]. By regulating protein synthesis, p70S6K and 4E-BP1 also control cell growth and hypertrophy, which are important processes for neoplastic progression. Hence targeting the mTOR pathway could have many effects on the regulation of cellular growth.

Many of the mRNAs encoding the previously mentioned genes contain 5'untranslated regions which are G+C rich and difficult to translate and referred to as weak mRNAs [35]. 4E-BP1 forms a complex with these mRNAs and other binding factors allowing the translation of these weak mRNAs [35,53-58]. Rapamycin and mTOR kinase inhibitors suppress the translation of these critical mRNAs involved in cell survival and growth.

**Control of Apoptotic Regulatory Molecules by the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR Pathways**

These two pathways regulate the activity of many proteins involved in apoptosis. In the following section, we will mainly discuss the effects of these pathways elicited by post-translational mechanisms [2, 3, 58-62], although it should be noted that both ERK and Akt also phosphorylate transcription factors that influence the transcription of the Bcl-2 family of genes as well as other important genes involved in the regulation of apoptosis [2, 4, 35, 60-62]. Many of the effects of the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways on apoptosis are mediated by ERK or Akt phosphorylation of key apoptotic effecter molecules (e.g., Bcl-2, Mcl-1, Bad, Bim, CREB, Foxo, Caspase-9 and many others) [2, 4, 35, 59-62]. In addition, both pathways regulate the translation of weak mRNAs. ERK, p90Rsk-1, MNK1/2 and p70S6K regulate the phosphorylation of many of the proteins involved in the key complex required for the translation of the weak mRNAs [35,44,56,57]. In some cases, members of the two pathways (e.g., p90Rsk-1 and p70S6K) will phosphor-
Figure 3. Interactions between the Ras/Raf/MEK/ERK, Ras/PI3K/PTEN/mTOR and Wnt/β-Catenin Pathways that Result in the Regulation of Protein Translation and Gene Transcription. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can affect protein translation by complex interactions regulating the mTORC1 (grouped together in a purple box) and mTORC2 (grouped together in a blue box) complexes. GF stimulation results in GFR activation which can activate both the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways. Akt can phosphorylate and inhibit the effects of GSK-3β, TSC2 and PRAS-40 (indicated in red ovals), which result in mTORC1 activation. ERK and PDK1 can phosphorylate p90RSK (indicated in green ovals), which in turn can phosphorylate and inhibit TSC2 (indicated in red oval). Akt-mediated phosphorylation of GSK-3β also affects the Wnt/β-catenin pathway and EMT. Rapamycin targets mTORC1 and inhibits its activity and also results in inhibition of downstream p70S6K. The effects of rapamycin are complex as long term administration of rapamycin may prevent mTOR from associating with mTORC2 and hence full activation of Akt is prevented. However, rapamycin treatment may result in activation of PI3K, by inhibiting the effects of p70S6K on IRS-1 phosphorylation which results in PI3K and Akt activation. Also rapamycin treatment may result in the activation of ERK in some cells, presumably by inhibition of the p70S6K mediated inhibition of IRS1. These later two effects of rapamycin could have positive effects on cell growth. Energy deprivation will result in the activation of serine/threonine kinase 11 (STK11 a.k.a LKB1) and AMP kinase (AMPK) which can result in TSC2 activation (indicated in red ovals) and subsequent suppression of mTORC1. In contrast Akt can phosphorylate and inhibit the activity of AMPK. Inhibition of PDK-1 activity can also result in activation of mTORC1, presumably by suppression of p70S6K and hence inhibition of IRS1 (indicated in red oval) effects on PI3K activity. The PTEN, TSC1, TSC2 and LKB1 tumor suppressor genes all converge on the mTORC1 complex to regulate protein translation. Thus the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can finely tune protein translation and cell growth by regulating mTORC1. Rapamycin can have diverse effects on these processes. Also these pathways can interact with the Wnt/β-catenin pathway which is important in developmental processes, EMT and CICs. Upon activation of the Wnt pathway, β-catenin forms a complex with Bcl-9, PYGO, plakoglobin and TCF/LEF which result in the transcription of critical genes including cyclin D1, c-Myc, SALL4 and PPARδ.
ULATE THE SAME MOLECULE IN THE TRANSLATION COMPLEX AT THE SAME SITE E.G. RIBOSOMAL PROTEIN S6 (rpS6) [57, 58]. HOWEVER, THE KINETICS OF PHOSPHORYLATION OF rpS6 BY THE TWO KINASES DIFFERS. THUS THESE TWO PATHWAYS REGULATE THE ACTIVITY OF THIS TRANSLATION COMPLEX WHICH IS RESPONSIBLE FOR THE TRANSLATION OF CERTAIN WEAK MRNAS INVOLVED IN REGULATION OF APOPTOSIS. McI-1 IS AN EXAMPLE OF A WEAK mRNA AND IT PLAYS KEY ROLES IN THE REGULATION OF APOPTOSIS.

ABERRANT REGULATION OF APOPTOSIS IS CRITICALLY IMPLICATED IN CANCER AS WELL AS MANY OTHER DISEASES (E.G., INFLAMMATION, AUTO-IMMUNE DISEASES). THEREFORE CONTROLLING THE ACTIVITY OF THE Ras/Raf/MEK/ERK AND Ras/PI3K/PTEN/Akt/mTOR PATHWAYS HAVE BEEN KEEN PHARMACEUTICAL OBJECTIVES FOR MANY YEARS. THE ACTIVITY OF MANY KEY COMPONENTS IN APOPTOTIC CASCADES IS SENSITIVE TO INHIBITORS THAT TARGET THESE PATHWAYS.

Akt regulates the apoptotic response to a variety of stimuli via its ability to interact with a number of key players in the apoptotic process [2,4,61,62]. Akt can directly phosphorylate BAD on S136, causing its inactivation preventing it from interacting with anti-apoptotic members of the Bcl-2 family of proteins (Bcl-2, Bcl-XL) [29,62]. Activated Akt can inhibit the release of cytochrome c from the mitochondria, which is a potent activator of the apoptotic caspase cascade [59]. The Akt target, Foxo-3 is capable of upregulating Fas ligand (Fas-L) and Bim, two very important molecules that are potent inducers of apoptosis; however, when inactivated by Akt, Foxo-3 is localized to the cytosol where it is unable to augment expression of these genes [28,60]. Akt can also phosphorylate Bim which inhibits its proapoptotic activity [61]. In concert, these events caused by Akt activation affect the survival status of the cell.

FREQUENT ONCOGENIC MUTATIONS AT MEMBERS OF THESE PATHWAYS RESULT IN ACTIVATION: RATIONALE FOR THERAPEUTIC TARGETING OF THESE PATHWAYS

Effective targeting of signal transduction pathways activated by mutations and gene amplification may be an appropriate approach to limit cancer growth, metastasis, drug resistance as well as aging. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can be activated by mutations/amplifications of upstream growth factor receptors. The abnormal production of growth factors can result in receptor activation which in turns mobilizes the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR cascades. An illustration of some of the receptors, exchange factors, kinases and phosphatases that are mutated/amplified in human cancer and how they may impact the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR cascades is presented in Figure 4.

Perhaps one of the biggest advances in medical science in the 1980’s was the confirmation of the proto-oncogene hypothesis, that predicted that the human genome contains genes related to viral oncogenes which when mutated could cause human cancer [4,7,19,35,62-84]. Key genetic members of the Ras/Raf/MEK/ERK pathway [e.g., RAS, RAF, MEK (rarely) [81-84], the downstream transcription factor (ETS) the Ras/PI3K/PTEN/Akt/mTOR (e.g., PIK3CA, AKT, PTEN) pathway and upstream receptors (e.g., ERBB1 (EGF-R), ERBB2 (HER2), PDGFR, KIT, FLT3, FMS) were shown to fulfill this hypothesis as they were sometimes mutated/amplified/deleted in specific human cancers. The RAS, RAF, PIK3CA, AKT, ERBB1, KIT, FMS and ETS oncogenes are also contained as viral oncogenes in the genomes of certain retroviruses that cause cancer in animals [2,7,35,62]. Furthermore, genetic mutations at these cellular oncogenes often alter sensitivity to specific targeted therapeutic approaches. Thus many of the genes in these two signal transduction pathway can cause cancer under the appropriate conditions.

Mutation of Upstream Receptors that Activate the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR Pathways in Human Cancer

Amplification/overexpression of HER2 (human epidermal growth factor receptor, a.k.a., c-ErbB-2, (ERBB2)) is an important cause of sporadic breast cancer that occurs in approximately 30% of breast cancer. HER2 is a receptor tyrosine kinase (RTK) [85]. HER2 can heterodimerize with c-ErbB-3 which has six docking sites for PI3K. While a normal breast cell possesses 20,000 to 50,000 HER2 molecules, amplification of this gene in HER2+ cancers can increase levels of HER2 up to 2,000,000 molecules per cell [85]. Overexpression of HER2 is linked to comedo forms of ductal carcinoma in situ (DCIS) and occurs in approximately 90% of these cases. HER2 overexpression will lead to increased expression of both the Ras/PI3K/Akt/PTEN/mTOR and Ras/Raf/MEK/ERK pathways. Association of genes that regulate signal transduction pathways with breast cancer implies an important role of these pathways in neoplasia.

In acute myeloid leukemia (AML), activation of the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathway can result from mutated upstream targets such as class III RTKs. These include point mutations such as FLT3-tandem duplications (FLT3-ITD) and mutated c-KIT, which are present in 35-40% of all AML
Mutations in upstream signaling molecules such as KIT and FLT3 are believed to activate the downstream signal transduction cascades, such as Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways.

Mutations at RAS in Human Cancer

Mutations that lead to expression of constitutively-active Ras proteins have been observed in approximate-
ly 20 to 30% of human cancers [7,63-69]. The frequency of RAS mutations and other key genes in the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways in various types of cancers is presented in Table 1. Often point mutations are detected in RAS genes in cancer cells from patients which enhance Ras activity. Genome RAS amplification or overexpression of Ras, perhaps due to altered methylation of its promoter region, are also detected in some tumors [7,63-69]. In cholangiocarcinoma, KRAS gene mutations have been identified in 45% of examined tumors [7]. Ras mutations are present in up to 20% of AML [67] and are another major cause of activation of this cascade. The frequency of KRAS mutations is very high (~80%) in advanced pancreatic cancers [7,63]. Mutations that result in increased Ras activity often perturb the Raf/MEK/ERK and also the PI3K/PTEN/Akt/mTOR cascades [7].

A key event in the activation of the Ras protein is farnesylation. Inhibitors that target the enzyme farnesyl transferase (FT) have been developed with the goal of inhibiting farnesylation. Inhibitors that target the enzyme farnesyl transferase (FT) have been developed with the goal of inhibiting farnesylation. The lack of usefulness of FTIs may be due to multiple reasons. First, there are many proteins that are regulated by FT and K-Ras to a lesser extent, N-Ras can also be modified by geranylgeranyltransferase (GGT). This modified N-Ras is still able to support the biological requirement of Ras in the cancer cell. Geranylgeranylation of K-Ras and N-Ras become critical only when farnesylation is inhibited. The majority of RAS mutations in humans occur in KRAS, which is followed by NRAS [7,67]. The mutation rate at HRAS is a distant third [7]. Hence, it is very possible that the effects that FTIs had in initial clinical trials were not due to inhibition of mutant RAS genes present in the cell, but in fact resulted from non-specific effects which are related to the first point mentioned. Another important target of FTIs is the Rheb protein (Ras homologue enriched in brain) (See Figure 2). Rheb, another GTP binding/exchange protein, plays key roles in regulating mTORC1 and controlling the efficiency of protein translation [4,19,35].

Mutations at RAF in Human Cancer

Prior to 2003, it was believed that the RAF oncogenes were not frequently mutated in human cancer. There are three RAF genes in humans, (ARAF, BRAF and CRAF (a.k.a. Raf-1) encoding three distinct proteins with diverse and common functions. With the advent of improved methods of DNA sequencing, it was demonstrated that BRAF is frequently mutated in melanoma (27 to 70%), papillary thyroid cancer (36 to 53%), colorectal cancer (5 to 22%), cholangiocarcinoma (22%), ovarian cancer (30%), and a small minority of lung cancer patients (1-3%) [70-75]. BRAF mutation occurs in approximately 7% of all cancers [70-73]. In contrast, CRAF and ARAF are not believed to be frequently mutated in human cancer [80-81].

It was proposed that the structures of B-Raf, Raf-1 and A-Raf kinases may dictate the ability of activating mutations to occur at, and be selected in, the genes encoding these proteins, which can permit the selection of oncogenic forms [75]. These predictions have arisen from the solved structure of B-Raf [75]. Like many enzymes, B-Raf is proposed to have small and large lobes, which are separated by a catalytic cleft. The structural and catalytic domains of B-Raf and the importance of the size and positioning of the small lobe may be critical in its ability to be stabilized by certain activating mutations. In contrast, the functionally similar mutations in ARAF and CRAF are not predicted to result in small lobe stabilization, this may prevent or hinder the selection of mutations at ARAF and CRAF, which would result in activated oncogenes [75].

The most frequent mutation detected at the BRAF gene is a change at amino acid 600, which converts a Val to Glu (Val600→Glu, V600E) [72]. This BRAF mutation accounts for > 90% of the BRAF mutations found in melanoma and thyroid cancer. BRAF mutations may arise in certain cells that express high levels of B-Raf as a result of hormonal stimulation. Certain hormonal signaling events will elevate intracellular cAMP levels, which result in B-Raf activation, leading to proliferation. Melanocytes and thyrocytes are two such cell types that have elevated B-Raf expression, as they are often stimulated by the appropriate hormones [76]. Moreover, it is thought that B-Raf is the most important kinase in the Ras/Raf/MEK/ERK cascade [75]. In some models, wild-type (WT) and mutant B-Raf are proposed to activate Raf-1, which then activates MEK and ERK [77,78].

A number of pharmaceutical and biotechnological companies have developed inhibitors that specifically target mutant B-Raf alleles (mutant-allele specific inhibitors), which do not inhibit WT B-Raf [3].

In many cancers with BRAF mutations, the mutations are believed to be initiating events and also the driver mutations, but are not sufficient for complete neoplastic transformation [35,65,66,72-75]. Mutations at other genes (e.g., in components of the Ras/PI3K/PTEN/Akt/mTOR pathway) have been hypothesized to be also necessary for malignant transformation in some cancers. Moreover, there may
Table 1

Mutations of the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Pathways in Human Cancer

| Gene          | Cancer Mutated At                        | Approximate Reported Frequency | Reference |
|---------------|------------------------------------------|-------------------------------|-----------|
| **RAS**       | Many different types including pancreatic, acute myeloid leukemia, endometrial, lung, colorectal | 20-25% all human cancers, KRAS mutations account for about 85%, NRAS for about 15%, HRAS for <1% | 7         |
| **KRAS**      | Pancreatic                               | 90%                           | 7         |
| **HRAS, KRAS, NRAS** | Thyroid (papillary)                          | 60%                           | 7         |
| **HRAS, KRAS, NRAS** | Thyroid (follicular)                          | 55%                           | 7         |
| **KRAS**      | Colorectal                                | 45%                           | 7         |
| **KRAS, NRAS** | Seminoma                                  | 45%                           | 7         |
| **NRAS, KRAS** | Myelodysplastic syndrome                   | 40%                           | 7         |
| **KRAS**      | Non Small Cell Lung Carcinoma             | 35%                           | 7         |
| **NRAS**      | Acute myelogenous leukemia                | 30%                           | 7         |
| **NRAS**      | Liver                                     | 30%                           | 7         |
| **KRAS**      | Endometrial                               | 20%                           | 7         |
| **NRAS**      | Melanoma                                  | 15%                           | 7         |
| **HRAS**      | Bladder                                   | 10%                           | 7         |
| **HRAS**      | Kidney                                    | 10%                           | 7         |

**BRAF** is activated in approximately 7% all cancers, highest in melanoma, often activated by point mutations.

| **BRAF**      | Melanoma                                  | 27-70%                        | 72        |
| **BRAF**      | Papillary Thyroid                         | 36-53%                        | 72        |
| **BRAF**      | Serous Ovarian                            | 30%                           | 72        |
| **BRAF**      | Colorectal                                 | 5-22%                         | 72        |

**PIK3CA** is often activated by point mutations, also by gene amplification.

| **PIK3CA**     | One of the most frequently mutated kinases in human cancer | >30% solid cancers          | 106, 110  |
| **PIK3CA**     | Breast                                    | 8-40%                        | 106, 108, 110 |
| **PIK3CA**     | Endometrial                               | 23-36%                       | 106, 110  |
| **PIK3CA**     | Hepatocellular                            | 36%                          | 106, 108, 110 |
| **PIK3CA**     | Colon                                     | 19-32%                       | 110       |
| **PIK3CA**     | Prostate                                  | 29%                          | 31        |
| **PIK3CA**     | Glioblastoma                              | 5-27%                        | 106, 110  |
| **PIK3CA**     | Head/Neck Squamous Cell                   | 33%                          | 106, 110  |

RAS genes can be activated by point mutations, gene amplifications and other mechanisms.
| PIK3CA          | Tissue                          | Frequency | Reference |
|-----------------|---------------------------------|-----------|-----------|
| Gastric         | 25%                             | 106, 110  |
| Urinary Track   | 17%                             | 31        |
| Anaplastic Oligodendroglioma | 14%                           | 106, 110  |
| Ovarian         | 6-12%                           | 110       |
| Intraductal Papillary Mucinous Neoplasm Carcinoma of the pancreas | 11%         | 110       |
| Upper Digestive Track | 10%                         | 31        |
| Stomach         | 8%                              | 31        |
| Esophagus       | 7%                              | 31        |
| Oral Squamous Cell | 7%                           | 110       |
| Pancreas        | 6%                              | 31        |
| Medulloblastoma | 5%                              | 110       |
| Lung            | 4%                              | 110       |
| Hematopoietic & Lymphoid | 4%                           | 31        |
| Skin            | 3%                              | 31        |
| Anaplastic Astrocytoma | 3%                           | 110       |
| Thyroid         | 2%                              | 31        |

*PTEN* often inactivated by deletion, gene methylation, protein stability and other genetic mechanisms.

| PTEN            | Tissue                          | Frequency | Reference |
|-----------------|---------------------------------|-----------|-----------|
| Endometrial     | 38%                             | 31        |
| Central nervous system | 20%                         | 31        |
| Skin            | 17%                             | 31        |
| Prostate        | 14%                             | 31        |
| Colon           | 9%                              | 31        |
| Urinary track   | 9%                              | 31        |
| Lung            | 8%                              | 31        |
| Ovary           | 8%                              | 31        |
| Breast          | 6%                              | 31        |
| Hematopoietic & Lymphoid | 6%                           | 31        |
| Thyroid         | 5%                              | 31        |
| Stomach         | 5%                              | 31        |
| Liver           | 5%                              | 31        |
| Upper aerodigestive track | 4%                         | 31        |
| Esophagus       | 1%                              | 31        |
| Pancreas        | 1%                              | 31        |

*AKT* is infrequently mutated in human cancer but *AKT2* gene can undergo amplification in certain cancers.

| AKT1            | Tissue                          | Frequency | Reference |
|-----------------|---------------------------------|-----------|-----------|
| Thryoid         | 5%                              | [www.sanger.ac.uk/perl.genetics/CGP/cosmic](www.sanger.ac.uk/perl.genetics/CGP/cosmic)|
| Breast          | 3%                              | [www.sanger.ac.uk/perl.genetics/CGP/cosmic](www.sanger.ac.uk/perl.genetics/CGP/cosmic)|
| Endometrial     | 3%                              | [www.sanger.ac.uk/perl.genetics/CGP/cosmic](www.sanger.ac.uk/perl.genetics/CGP/cosmic)|
be certain situations where certain potent BRAF mutations (Val600→Glu) and RAS mutations are not permitted in the same cell, as they might result in hyperactivation of Ras/Raf/MEK/ERK signaling and expression, which could lead to cell cycle arrest [75]. In contrast, there are other cases that require both BRAF and RAS mutations for transformation. The BRAF mutations in these cases may result in weaker levels of B-Raf activity which is insufficient for abnormal proliferation [65,66,75,77,78]. It should be pointed out that RAS mutations may also result in activation of the Ras/PI3K/Akt/mTOR pathway. Different BRAF mutations have been mapped to various regions of the B-Raf protein. Mutations at BRAF that result in low kinase activity may signal through Raf-1 [75,77,78]. Heterodimerization between B-Raf and Raf-1 proteins may allow the impaired B-Raf to activate Raf-1. Other mutations, such as Asp 593→Val, may activate alternative signal transduction pathways [75]. One study has observed that mutated alleles of CRAF are present in therapy-induced acute myelogenous leukemia (t-AML) [80]. This t-AML arose after chemotherapeutic drug treatment of breast cancer patients. The mutated CRAF genes were transmitted in the germ line, thus, they were not spontaneous mutations in the leukemia, but they may be associated with the susceptibility to induction of t-AML in the breast cancer patients studied. Subsequent studies demonstrated that blast cells from patients with the CRAF germline mutations also had loss of the tumor and metastasis suppressor Raf kinases inhibitor protein (RKIP) [81]. The importance of RKIP was determined by transfection experiments with either siRNA directed against RKIP or expression vectors overexpressing RKIP [81]. The levels of RKIP were determined to influence the levels of CRAF-mediated transformation as high levels of RKIP suppressed CRAF-mediated transformation, while low levels enhanced CRAF-mediated transformation [81]. Decreased RKIP expression has also been observed in some cutaneous squamous cell carcinomas which also displayed decreased BRAF expression [79]. Thus mutation at both BRAF and CRAF have been detected in certain cancer patients and other studies have shown that the levels of mutant and WT B-Raf, Raf-1 and RKIP will influence the levels of transformation observed, hence there is a strong basis for the development of Raf inhibitors [3]. Mutations downstream of Raf in the Ras/Raf/MEK/ERK cascade have not been frequently detected in human cancer although there are some rare germline mutations detected at MEK1 and MEK2 in cardiofaciocutaneous syndrome (CFC) [82]. There are also mutations at other components of the Ras/Raf/MEK/ERK pathway including KRAS and BRAF in CFC. There are mutations at components of

| AKTI  | Ovary       | 1% | www.sanger.ac.uk/perl.genetics/CGP/cosmic |
|-------|-------------|----|------------------------------------------|
| AKTI  | Urinary track | 1% | www.sanger.ac.uk/perl.genetics/CGP/cosmic |
| AKTI  | Prostate    | 1% | www.sanger.ac.uk/perl.genetics/CGP/cosmic |
| AKTI  | Large Intestine | 1% | www.sanger.ac.uk/perl.genetics/CGP/cosmic |
| AKTI  | Hematopoietic & Lymphoid tissue | 1% | www.sanger.ac.uk/perl.genetics/CGP/cosmic |
| AKTI  | Head and Neck squamous cell carcinomas | 30% amplified | 31 |
| AKTI  | Pancreatic  | 20% amplified | 31 |
| AKTI  | Ovarian     | 12% amplified | 31 |
| AKTI  | Breast      | 3% amplified | 31 |
| AKTI  | Urothelial Carcinoma | 15% | 159 |

TSC1/TSC2 are inactivated by point mutations, deletion and other genetic mechanisms. Only TSC1 is associated with some human cancers.
the Ras/Raf/MEK/ERK pathway in the related Costello and Noonan syndromes, including: SOS, and \textit{PTPN11} (Shp2) in Noonan syndrome and \textit{HRAS} mutations in Costello syndrome [83]. These germline mutations confer sensitivity to MEK inhibitors. \textit{MEK1} but not \textit{ERK2} mutations have been observed in some melanomas and colon carcinomas [84].

**Activation of the Ras/Raf/MEK/ERK Cascade in the Absence of Mutations in the Pathway**

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most prevalent cause of cancer mortality, accounting for approximately 6% of all human cancers and more than 600,000 deaths annually worldwide [85,86]. Although the clinical diagnosis and management of early-stage HCC has improved significantly, HCC prognosis is still extremely poor. Therefore, investigating HCC pathogenesis and finding new diagnostic and treatment strategies is important.

Signaling via the Ras/Raf/MEK/ERK cascade plays a critical role in liver carcinogenesis [86-91]. Although mutations of Ras and Raf occur infrequently in HCC, a recent study demonstrated that activation of Ras pathway occurred in 100% of HCC specimens analyzed when compared with non-neoplastic surrounding tissues and normal livers [91].

In addition, activation of Ras/Raf/MEK/ERK pathway in HCC may be due to down-regulation of Ras inhibitors Sprouty and the Sprouty-related protein with Ena/vasodilator-stimulated phosphoprotein homology-1 domain (Spred-1) and Spred-2 proteins [92,93]. It has been shown that the expression of Spred-1 and -2 in human HCC tissues is frequently decreased, in comparison to adjacent non-tumorous tissues. This decreased expression inversely correlated with the incidences of tumor invasion and metastasis [92]. Moreover, ectopic Spred expression inhibited HCC cell proliferation both \textit{in vitro} and \textit{in vivo}, which was associated with reduced ERK activation, suggesting that Spred could be both a novel prognostic factor and a new therapeutic target for human HCC [93].

Down-regulation of RKIP expression is a major factor in activation of the Ras/Raf/MEK/ERK pathway during human hepatocarcinogenesis [94]. These studies indicate the complex interplay of various genes that serve to regulate the Ras/Raf/MEK/ERK pathway. Deregulation of their expression by various mechanisms (\textit{e.g.}, promoter methylation, point mutations, post-translational mechanisms) may result in Ras/Raf/MEK/ERK pathway activation in the absence of detectable mutations at either \textit{RAF} or \textit{MEK}. Hence, the Ras/Raf/MEK/ERK cascade is a therapeutic target in HCC [3,95,96].

Obesity is another important contributing factor for the development of HCC [97]. The important role of Ras/Raf/MEK/ERK signaling has also been suggested for HCC progression in obese patients. A possible explanation for risk associated between obesity and HCC comes from the study of Saxena et al., which for the first time demonstrated that leptin, a key molecule involved in the regulation of energy balance and body weight control, promotes HCC growth and invasiveness through activation of Ras/Raf/MEK/ERK signaling [98].

Other well known risk factors for HCC such as hepatitis B and C viruses (HBV and HCV) also utilize the Ras/Raf/MEK/ERK pathway for the control of hepatocyte survival and viral replication [99]. Among the four proteins encoded by HBV genome, HBx is involved in heptocarcinogenesis. HBx activates Ras/Raf/MEK/ERK signaling cascade [100]. Among HCV components, the core protein has been reported to activate the Ras/Raf/MEK/ERK pathway and thereby might contribute to HCC carcinogenesis [101, 102]. Therefore, these studies suggest that the Ras/Raf/MEK/ERK pathway is a novel therapeutic target that could be exploited for the treatment of HCC resulting from HBV and HCV infection. \textit{microRNAs} (miRNAs) may play a key role in regulating HCV translation [103]. Protein translation is regulated by the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways and may be a therapeutic target for HCC [104]. The interacting Wnt/\textit{β}-catenin pathway also has effects on HCC [105].

**Mutations at PIK3CA in Human Cancer**

The PI3K \textit{p110α} catalytic subunit (\textit{PIK3CA}) gene is currently the most frequently mutated kinase in human cancer. \textit{PIK3CA} is mutated in approximately 25% of breast, 32% of colorectal, 30% of endometrial, 27% of brain, 25% of gastric, 4% of lung cancers [106-110] (Table 1). These mutations are clustered in small hot-spot regions within the helical (E542, E545) and kinase (H1047) domains [106-110]. The locations of these mutations have been recently critically evaluated [110]. These mutations frequently result in activation of its kinase activity [110]. Furthermore increased expression of the Ras/PI3K/Akt/mTOR pathway also occurs frequently in some cancers as the \textit{PIK3CA} gene is amplified in approximately 40% of ovarian cancers [109].
Activation of PI3K/PTEN/Akt/mTOR signaling through mutation, inactivation or silencing of pathway components occurs in various malignancies, including liver cancer [111]. Deregulation of this pathway has clinical importance in HCC. For example, recent data from genomic sequence of HCC samples identified mutations in PIK3CA in 50% of patients with poor prognosis, survival length < 3 years following partial liver resection, and only 10% of the HCC patients with a good prognosis had mutation in PIK3CA [111]. The identified mutations were restricted to residues H1047 in 61.1%, to E545 in 33.3%, and to E542 in 5.5% of cases, and as a consequence this result in gain of enzymatic function and consequently in oncogenic activity of PI3K [111].

**Mutations at PTEN in Human Cancer**

Germline PTEN mutations are present in approximately 80% of patients with Cowden syndrome [112]. This disease, which is also known as multiple hamartoma syndrome, is another familial syndrome that includes many different types of cancer conditions including early onset breast cancer. Mutations have been reported to occur at PTEN in breast cancer in varying frequencies (5-21%) [113,114]. Loss of heterozygosity (LOH) is probably more common (30%) [114]. Mutations at certain residues of PTEN, that are associated with Cowden’s disease, affect the ubiquitination of PTEN and prevent nuclear translocation. These mutations leave the phosphatase activity intact [115]. Inhibition of PTEN activity leads to centromere breakage and chromosome instability [34]. Thus PTEN has diverse activities.

Akt and mTOR phosphorylation are frequently detected in ovarian and endometrial cancers. An early occurrence in endometrial cancer is the loss of functional PTEN activity by mutation or other mechanisms, this occurs in approximately 40-80% of patients [116]. Since the loss of PTEN results in activation of Akt, that in turn up-regulates mTOR activity, cancer cells deficient in PTEN are thought to be major targets of mTOR inhibitors.

The best evidence that strongly supports the connection between PTEN-suppression and liver carcinogenesis comes from genetic studies. All mice with PTEN-deficient hepatocytes exhibited liver adenomas and 66% of them developed HCC [117]. In these mice, hepatocytes were hyperproliferative and displayed an abnormal activation of Akt [117]. Furthermore, although mutations in the PTEN gene rarely occur in HCC, frequent loss of heterozygosity of PTEN allele has been identified in 20-30% of HCC patients [118-121]. In addition, down-regulation of PTEN expression may be partly due to PTEN promoter methylation [122].

PTEN expression plays a critical role in HCC progression and patient’s outcome. Patients with high expression of PTEN had a significantly better overall survival than patients with low PTEN expression [123]. As mentioned above, hepatitis viruses protect hepatocytes from apoptotic cell death by promoting the activation of Ras/PI3K/Akt/mTOR survival pathway [124,125]. Among the four proteins encoded by HBV genome, HBx has been reported to be involved in hepatocarcinogenesis. It has been reported that HBx expression downregulated PTEN expression in hepatocytes [125,125]. In contrast, PTEN expression in liver cells downregulated HBx-induced PI3K and Akt activities [126]. Therefore, these studies suggest the possible use of PTEN as a target in therapeutic approaches for the treatment of at least those HCC caused by HBV infection.

In some cancer settings, PTEN and BRAF mutations appear to interact. Two recent papers have highlighted the hypothesis of mutant BRAF- and PTEN-loss-driven carcinogenesis in mouse models. In a study by Dhomen et al., inducible expression of B-RafV600E was sufficient to induce multiple melanocytic lesions including skin hyperpigmentation, dysplastic nevi and melanoma [127]. Tumor cells from these B-RafV600E mice displayed both melanoma growth and melanocyte senescence in this system. Approximately 70% of these mice developed melanomas that exhibited histological and molecular characteristics similar to that of human melanoma and were able to colonize the lungs in nude mice [127]. In contrast, another group of researchers generated mice that conditionally-expressed melanocyte-specific B-RafV600E that were only able to induce benign melanocytic hyperplasias and were unable to progress any further over a 15-20 month period [128]. However, B-RafV600E expression in a PTEN gene-silenced background led to the production of melanoma with 100% establishment, short latency and metastasis to lymph nodes and lungs. This development was prevented by the treatment of mice with either the mTOR inhibitor rapamycin or the MEK1/2 inhibitor (PD0325901). Moreover, while combination treatment with rapamycin or PD0325901 led to the reduction of established tumors, upon termination of drug treatment the melanomas reappeared the presence of drug resistant melanoma-initiating cells in these mice. Overall, these two papers further validated the mutant B-Raf/MEK/ERK and the PI3K/Akt/mTOR pathways, as promising therapeutic targets in melanoma.

Mutations and hemizygous deletions of PTEN have been detected in AML and non Hodgkin’s lymphoma (NHL) and other cancers [129,130]. Thus the PTEN
gene is a critical tumor suppression gene, frequently mutated in human cancer.

**Alterations of PTEN Expression in Human Cancer**

Phosphorylation (inactivation) of PTEN has been associated with increased Akt-activity. Although many groups have investigated the PTEN-phosphorylation status in leukemia and lymphoma, its relevance concerning Akt-activation is still not clear [129-133]. PTEN phosphorylation as well as low or absent PTEN expression has been observed in AML.

Furthermore, the level of PTEN expression does not always correlate with the degree of phosphorylation of Akt [129]. Although the picture concerning PTEN-inactivation and corresponding Akt-activation is not clear, in vivo studies indicate, that PTEN dysregulation promotes leukemogenesis. PTEN-deficient hematopoietic stem cells display dysregulated cell cycle progression, and the mice develop a myeloproliferative disease which leads to leukemic transformation [131]. In T-acute lymphoblastic leukemia (T-ALL), PTEN-downregulation is also closely correlated with Akt-activation [132,133]. To discern the role of PTEN for Akt-activation, it may be useful to exclude concomitant causes for Akt-activation such as mutant upstream targets and to include the investigation of regulators of PTEN such as c-Myc and Notch/Hes1 [132,133].

PTEN promoter methylation leads to low PTEN expression [134]. In one study, 26% of primary breast cancers had low PTEN levels that correlated with lymph node metastases and poor prognoses [135].

Other mechanisms important in the regulation of PTEN are miRNAs. Certain miRNAs have been shown to regulate PTEN protein expression. mi-214 induces cell survival and may contribute to oncogenesis and drug resistance (see below) by binding the 3’ untranslated region (3’UTR) of PTEN which prevents PTEN mRNA translation and leads of overexpression of downstream Akt [136].

**Mutations at SHIP Phosphatase in Human Cancer**

The SHIP-1 phosphatase has been implicated as a suppressor of hematopoietic transformation as it basically can prevent Akt-activation [137]. SHIP-1-deficient mice develop a myeloproliferative disease [138] and an inactivating point mutation (SHIP V684E) has been observed in approximately one of thirty AML cases [137]. Also another mutation, SHIP Q1154L, has been observed in AML, but was even less frequent (1 of 192 cases) [138]. Though some studies confirmed, that SHIP-1 is a leukemia suppressor [137,138] it is unlikely that SHIP1 mutations are a frequent cause of Akt-activation in AML. Disruption of PTEN or SHIP activity by various genetic mechanisms could have vast effects on different processes affecting the sensitivity of different cancers to various therapeutic approaches.

**Mutations of AKT in Human Cancer**

The roles that Akt plays in cancer are complex. Akt can be activated by genetic mutations, genome amplifications and more commonly by mutations in upstream signaling components. Amplification of Akt-2 was observed in human ovarian carcinomas [139]. Increased levels of Akt are detected in carcinomas of the breast, ovary and prostate and are associated with a poorer prognosis in comparison with tumors that do not display increased levels of expression. Akt is a member of a multi-gene family that consists of AKT1, AKT2 and AKT3. AKT1 has been reported to be mutated in some breast, colorectal, melanoma and ovarian cancers [140-142] (see below). AKT2 is not mutated frequently in human cancer. AKT2 is amplified in certain cancers (e.g., 12.1% ovarian and 2.8% breast carcinomas) [142]. A recent report documents the mutation of AKT3 in some melanoma samples [143].

AKT1 is mutated in 2 to 8% of breast, 6% of colorectal and 2% of ovarian cancers samples examined in one study [140]. This study documented an Akt mutation that results in a glutamic acid (E) for a lysine (K) substitution at amino acid 17 (E17K) in the PH domain. Cells with this AKT1 mutation have not been observed to have mutations at PIK3CA; a similar scenario is also frequently observed with RAS and BRAF mutations [144]. This AKT1 mutation alters the electrostatic interactions of Akt-1 which allows it to form new hydrogen bonds with the natural PtdIns ligand [140]. The PH domain mutation confers many different properties to the AKT1 gene. Namely the mutant AKT1 gene has: 1) an altered PH domain conformation, 2) is constitutively-active, 3) has an altered cellular distribution as it is constitutively-associated with the cell membrane, 4) morphologically transforms Rat-1 tissue culture cells and 5) interacts with c-Myc to induce leukemia in Eμ-Myc mice (Eμ = Enhancer of immunoglobulin μ gene, Myc = Myc oncogene originally isolated in avian myelocytomatosis virus) [140]. This PH domain mutated AKT1 gene does not alter its sensitivity to ATP competitive inhibitors, but does alter its sensitivity to allostERIC kinase inhibitors [140]. These results demonstrate that targeting the
kinase domain of Akt may not be sufficient to suppress the activity of various AKT genes that have mutations in the PH domain.

**Alterations of Akt Expression in Human Cancer**

Akt is often upregulated in cancer cells and its overexpression is associated with a poor prognosis. Increased expression of Akt can result from activating PIK3CA mutations or elimination or decrease in PTEN activity. Elevated Akt expression has also been associated with the pathology of pancreatic, glioma and prostate cancers [145-148].

Pancreatic cancer cells have elevated IGF-1R expression and it is well known that Akt regulates IGF-1R expression [149]. This Akt effect on IGF-1R has been suggested to be responsible for the invasiveness of pancreatic cancer cells. Active Src can also activate Akt, and both Src and Akt up-regulate IGF-1R expression in this cancer. It has been demonstrated that IGF-I is expressed in the surrounding stromal cells but not in the cancer cells. This IGF-1 expression may serve as a paracrine growth factor to activate the IGF-1R pathway and the downstream Ras/PI3K/Akt/mTOR pathway in pancreatic cells.

Cyclooxygenase-2 (COX-2) is expressed at high levels in some primary endometrial tumors and is associated with an aggressive phenotype [150]. Akt is elevated and PTEN is often mutated in these cancers. Recently, NF-κB activation has been shown to have oncogenic effects important in the control of apoptosis, cell cycle, differentiation and cell migration. Akt may exert its effects through the NF-κB pathway and COX-2 is the regulator of this pathway. Akt regulates COX2 gene and protein expression in endometrial cancers. This study was undertaken to examine the involvement of Akt in the regulation of NF-κB and COX-2 [150]. The expression of both inhibitor of NF-κB (IkB) and phosphorylated IkB were increased in the cells containing mutant PTEN genes. In contrast, there was no difference in NF-κB protein abundance between the cell lines, which differed in PTEN gene status. IkB phosphorylation by the PI3K pathway was inhibited by the PI3K inhibitors Wortmannin and LY294002. There was less NF-κB nuclear activity, less COX-2 expression and more apoptosis after inhibition of the PI3K pathway. Dominant negative (DN) Akt blocked IkB phosphorylation and decreased COX-2 expression. In contrast, introduction of constitutively-active Akt induced IkB phosphorylation and up-regulated COX-2 expression.

When PTEN is mutated, Akt signals via the NF-κB/IκB pathway to induce COX-2 expression in endometrial cancer cells. COX-2 can inhibit apoptosis, increase angiogenesis, and promote invasiveness. COX-2 also promotes inflammation/immunosuppression and conversion of procancers into carcinosgenes that contribute to tumorigenesis and a malignant phenotype. This study demonstrated that Akt signals via the NF-κB/IκB pathway to induce COX2 gene and protein expression in endometrial cancer [150].

Elevated Akt activity can also result in increased phosphorylation of mTOR. mTOR was found to be phosphorylated in AML blasts, along with its two downstream substrates, p70S6K and 4EBP-1, in a PI3K/Akt-dependent fashion [151]. Nevertheless, others failed to detect any relationship between PI3K/Akt signalling upregulation and p70S6K phosphorylation in AML primary cells [152]. This might occur via the Ras/Raf/MEK/ERK pathway activating mTOR via ERK phosphorylation [152]. The Ras/Raf/MEK/ERK pathway is frequently activated in AML [153]. Thus treatment of AMLs with Raf and MEK inhibitors is been investigated [3,154,155].

Akt is activated in HCC, which results in enhanced resistance to apoptosis through multiple mechanisms [101,156-158]. As an example, activation of the Akt pathway suppresses transforming growth factor-β (TGF-β) induced apoptosis and growth-inhibitory activity of CCAAT/enhancer binding protein alpha (CEBP-α). Activation of Akt is a risk factor for early disease recurrence and poor prognosis in patients with HCC [156]. Several mechanisms may be responsible for the activation of Akt. The high frequency of PIK3CA mutations and/or its upregulation in patients with shorter survival might be responsible for the Akt hyperactivation found in HCC with poor prognosis [118-124]. Selective epigenetic silencing of multiple inhibitors of the Ras pathway seems also to be responsible for the activation of Akt found in HCC [111]. Moreover, impaired expression of PTEN is involved in the regulation of Akt activity. Activation of Akt signaling and reduced expression of PTEN has been reported in 40%-60% of human HCC cases [111,118-124]. Some well known risk factors, HBV and HCV seem to utilize the Ras/PI3K/PTEN/Akt/mTOR pathway for the control of hepatocytes survival and viral replication [157,158]. Taken together, these data suggest that Ras/PI3K/Akt/mTOR pathway may represent an important therapeutic target for the treatment of HCC among patients with differing etiologies that lead to the development of this aggressive tumor.
Mutations of TSC1/TSC2 Genes in Human Cancer

Mutations in the tumor suppressor genes TSC1 and TSC2 are associated with a dominant genetic disorder, tuberous sclerosis [42,159]. Patients with mutant TSC genes develop benign tumors (hamartomas). In contrast to Cowden’s patients who have germline mutations at PTEN and the patients have a high propensity to develop multiple malignancies, TSC patients rarely develop multiple malignancies, and the patients have a high propensity to develop renal cell carcinomas (RCCs) or angiomylipomas [159]. This has been hypothesized to result from a lack of activation of Akt in cells that have mutant TSC1 or TSC2 as mTOR activity is expressed at higher levels which results in inhibition of Akt, perhaps via the effects of p70S6K on insulin regulated substrate-1 (IRS1) (Figure 3). TSC1 has been shown to be mutated in approximately 15% of urethelial carcinomas (bladder cancers) [159].

Altered Expression of Components Downstream of mTOR in Human Cancer

mTOR regulates translation by phosphorylating components of the protein synthesis machinery, including p70S6K and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) [160,161]. p70S6K phosphorylates the 40S ribosomal protein, rps6, leading to active translation of mRNAs [4]. In contrast, 4E-BP1 phosphorylation by mTORC1 on several amino acidic residues (S37; T46; S65; T70) results in the release of phosphoamino acid sequences in the 5' UTR largely dictates the efficiency of which an mRNA transcript will be translated. Most mRNAs contain short, unstructured GC-poor 5’ UTRs and are efficiently translated. In contrast, long, GC-rich sequences in the 5' UTR often hinder the ability of the eIF-4E complex to efficiently scan and initiate translation at the start codon [4,19,35]. These are called long and under normal circumstances these mRNAs are not efficiently translated, and are considered “weak” mRNAs [4,19,35]. However, upon Akt-mediated activation of mTOR, these latter mRNAs are highly and disproportionately translated. Interestingly, many of these weak mRNAs molecules encode oncogenic proteins involved in cell proliferation or survival (e.g., c-Myc, Mcl-1, cyclin-D, VEGF and survivin). These oncogenic mRNAs are therefore tightly regulated at the translation level and their accumulation in cancer cells strongly contributes to the malignant phenotype.

Several key proteins that are overexpressed as a consequence of mTOR activation include; c-Myc [162-164], cyclin D1 [164], and VEGF [165] and others. Cyclin D1 has been reported to be overexpressed in prostate cancer xenographs and metastases [166], while early stage prostatic lesions possess much lower levels of the protein [167]. A number of reports support the notion that mTOR signaling is a prominent feature of cancer progression and aging, as recurrent tumors have altered expression of a number of molecular targets of rapamycin including the above mentioned genes which encode “weak” mRNAs [168-171]. Hence mTOR inhibitors such as rapamycin may be effective in cancer therapy.

One central molecule involved in cell growth is p70S6K which is regulated by both the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways [4]. The p70S6K gene is amplified in approximately 9% of primary breast cancers and elevated levels of its mRNA transcripts are found in about 41% of the tumors [173,174]. It is known that some PTEN-deficient cells and tumors that are purported to grow in response to activated Akt are hypersensitive to mTOR inhibitors. p70S6K activity is reduced by mTOR inhibitors in PTEN-deficient cells and transgenic PTEN−/− mice [175,176].

Involvement of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR Pathways in Hormone-Independent Prostate Cancer

The progression of prostate cancer from androgen-dependent to androgen-independent tumors involves the alteration of the androgen receptor and/or the activation of pro-survival pathways, namely those of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR signaling cascades [177,178]. Research has shown that inhibition of one or both of these pathways has a more profound effect on tumor cell development and death making them very attractive as combinatorial targets in prostate cancer therapy. In the study by Wu et al., cells from the androgen-dependent cell line LNCaP were able to differentiate into neuroendocrine type cells upon androgen withdrawal from the culture media [177]. This differentiation was marked by a change in cellular morphology and expression of the chromogranin and neuron-specific enolase (NSE), as well as an increase in phosphorylated ERK and Akt. Inhibition of the Ras/PI3K/PTEN/Akt/mTOR pathway with the PI3K inhibitor LY294002 and the mTOR inhibitor Rapamycin reduced the expression of these neuroendocrine specific cell markers however the use of the MEK inhibitor U0126 appeared to have no effect [177]. In another study, Nkx3.1;Pten mutant mice were used as a preclinical model for the effects that inhibition of both Ras/Raf/MEK/ERK and
Ras/PI3K/PTEN/Akt/mTOR pathways would have on hormone-dependent and -independent prostate cancer growth [178]. The Nkx3.1;Pten mutant mouse model resembles that of human prostate cancer progression in which spontaneous PIN lesions form and progress to adenocarcinomas and eventually hormone refractory tumors upon androgen deprivation. Treatment of tumors from these mice both in vivo and in vitro with rapamycin and the MEK inhibitor PD0325901 were able to synergistically decrease their respective target pathway’s activation more effectively and at a lower IC50 compared to treatment with each agent alone [179]. Interestingly, although combination inhibitor therapy was somewhat effective at reducing tumor size and proliferation in the androgen-intact mouse model, the highest reduction in tumor growth from therapy was observed in the androgen-deficient mice [178]. In addition to the mouse study these authors were able to show, using human patient tissue microarrays, that aberrant activation of some of the Ras/PI3K/PTEN/Akt/mTOR pathway components (Akt, mTOR, p70S6K) are frequent in progressed human prostate tumors. In addition, activation of the Ras/Raf/MEK/ERK pathway coincides with a high percentage of these tumors as well, suggesting that combination inhibitor treatment along with hormone ablation could prove useful in human prostate cancer therapies [178].

**Interactions of p53 and the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways**

Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways are often regulated by the tumor suppressor p53. Furthermore p53 activity is likewise regulated by the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways. p53 is a critical tumor suppressor gene which encodes a transcription factor that is frequently mutated in human cancer [179-195]. P53 regulates the transcription of many genes whose protein products play critical roles in cell cycle progression, apoptosis, senescence, quiescence and aging. p53 is often activated after chemotherapeutic drug treatment and DNA damage [182,183,193-195]. There are complex interactions between p53, DNA damage responses and these two signaling pathways [180-195]. Akt can phosphorylate MDM-2 which leads to its proteasomal degradation and prevents it ability to interact with and destabilize p53 [4]. The p53 and MDM families of genes are critically involved in the response to DNA damage [183-185], apoptosis [185], senescence [186], metastasis [188], autophagy [190], chemosensitivity [191,195] and cellular aging [179,181,182]. Thus the ability to fine tune these pathways could significantly advance human health.

MDM-2 inhibitors such as Nutlin-3A increase p53 stability [179]. p53 can affect the transcription of the PTEN and other important gene involved in cell cycle regulation (e.g., p21Cip-1), apoptosis (e.g., Bax, Noxa, Puma) and cellular senescence [e.g., Yippee-like-3 (YPEL3)], [180,184-186,192]. Thus reactivation of p53 expression could enhance PTEN gene expression and hinder activation of Akt.

The Ras/Raf/MEK/ERK pathway can regulate p53 activity and p53 can also induce the activity of key components of this pathway [196-198]. ERK can phosphorylate p53 and alter its activity. Moreover, chemotherapeutic drugs such as doxorubicin can induce the p53 activity that in turn can activate the expression of the discoidin domain receptor (DDR) which can induce Ras and the downstream Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways [196-198].

In certain scenarios, increased p53 expression after chemotherapeutic drug treatment may lead to increased Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways activation, resulting in an undesired proliferative effect [195]. This may occur in certain cancer initiating cells (CICs) and be a component of their inherent drug resistance. In addition, Akt has critical roles in regulation of cell cycle progression [199-202]. Thus in those therapeutic scenarios where increased p53 activity is desired, it may also be prudent to also consider treatment with either a Raf or MEK inhibitor to decrease the activation of this proliferative pathway.

**Novel Roles of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR Pathways in Cancer and Aging**

In the previous sections, we have discussed the mechanisms of activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways in human cancers, predominantly by mutational based mechanisms. Recently the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways have been shown to have roles in cancer stem cells, senescence, aging and sensitivity to targeted therapy [203-245]. These additional functions of these pathways expand their important in human health.

An area of intense interest in cancer biology is the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC) [203-211]. The concept that the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways serve as key pathways in regulating CIC survival is beginning to emerge. CICs have unique properties as they can be...
both quiescent and also resistant to chemotherapeutic and hormonal based drugs [203]. However, under certain conditions, they resume proliferation and hence should be potentially susceptible to Ras, Raf, MEK, PI3K, Akt or mTOR inhibitors.

The PTEN gene has been shown to exert effects on CICs, especially in hematopoietic and breast cells [204-209]. In conditional PTEN knock-out mice, upon inactivation of PTEN, there is a transient increase in hematopoietic CICs and a myeloproliferative disease develops and the mice subsequently develop leukemia after 4-6 weeks [204]. If the mice are treated with rapamycin, the myeloproliferative disorder and leukemia are prevented. The initial leukemic CICs that arise after conditional PTEN deletion by themselves are not able to induce leukemia upon transfer into severe combined immuno deficiency (SCID)-recipient mice, but if the leukemic CICs were derived from the PTEN-conditional mice that had developed leukemia, they were able to transfer leukemia to the SCID-recipient mice, which could be prevented by rapamycin treatment [204]. Also the normal hematopoietic stem cells from the PTEN-conditional knock-out mice could repopulate the hematopoietic cell component of irradiated mice treated with rapamycin indicating that it is possible to selectively eliminate leukemic CICs.

PTEN also plays important roles in breast CICs [205,206]. If PTEN is mutated, Akt phosphorylates and inactivates glycogen synthetase kinase 3β (GSK-3β) which in turn regulates the activity of the Wnt/β-catenin pathway [Figure 3], as β-catenin is not phosphorylated by GSK-3β and not degraded. β-catenin can localize to the nucleus, perhaps due to Akt-mediated phosphorylation at S552 and exert its effects. β-catenin can then promote the expression of many genes such as cyclin D, c-Myc, SALL4 and peroxisome proliferator-activated receptor-δ (PPARδ) which are important in cell survival and EMT. The Ras/PI3K/PTEN/Akt/mTOR pathway performs key roles in the regulation of the size of the Aldefluor-positive cell population that are enriched in breast CICs. Treatment with the Akt inhibitor perifosine was able to target these cells both in in vitro and xenograft models [206]. In contrast, the chemotherapeutic drug docetaxel was unable to target the Aldefluor-positive cells and these cells were not sensitive to mTOR inhibitors, suggesting that the mTOR pathway was not involved in these breasts CIC. The studies by Korkaya et al. [206] indicate that targeting some breast CICs with perifosine may eliminate these cells that are responsible for tumor reappearance. Other studies have shown that breast CICs are resistant to chemotherapeutic drugs [212-214]. We have observed that some drug resistant breast cells that express properties similar to CICs display elevated activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR signaling cascades and that CICs can be isolated from these cell populations [215-217]. Our recent data suggests these CICs are more sensitive to MEK and mTOR inhibitors than either the parental or drug resistant cells from which they were derived [215]. Targeting the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/mTOR pathways could be very important in terms of CIC elimination.

Involvement of the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Pathways in Suppression Cellular Senescence and Premature Aging

The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways play key roles in regulation of diverse processes ranging from: autophagy DNA damage responses, cellular senescence and aging [217-237]. Treatment of cells induced to undergo senescence with MEK, PI3K and mTOR inhibitors will prevent the induction of cellular senescence and aging [219-221]. These experiments have led to innovative hypothesis that cellular senescence results from the hyper-activation of proliferative pathways. Drugs used to treat diabetes (e.g., Metformin) or inhibit signal transduction pathways (e.g., Raf, MEK, PI3K, mTOR inhibitors) can inhibit cellular proliferation and cellular aging [229-234]. Similar effects on the prevention of cellular senescence were observed with Resveratrol, the active component contained in the skins of red grapes which was shown to also inhibit mTOR and cellular senescence [229,230]. Additional studies have shown that the commonly-prescribed diabetes drug Metformin will also inhibit mTOR and prevent cellular aging [234]. Since both the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways interact to regulate the activity of mTOR and downstream components of this pathway which are critical for both mRNA stability and protein translation, it is believed that by inhibiting some of these key pathways, it may be possible to prevent cellular aging (See Figures 1-3).

CONCLUSIONS

Over the past 25 years, there has been significant progress in elucidating the involvement of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR cascades in promoting cell growth, regulating apoptosis, chemotherapeutic drug resistance and more recently, cellular senescence and aging. Initial seminal studies performed in the late 70’s and early 80’s elucidated that oncogenes were present in the genomes of avian and
murine retroviruses. Many of the viral oncogenes: ErbB, Fms, Ras, PI3K, Akt, Src, Abl, Raf, Fos, Jun, Ets and NF-κB (Rel) were subsequently identified as cellular genes which in some cases were captured by retroviruses. Now we know that these cellular genes are frequently abnormally regulated in human cancer. Furthermore mutations in human cancer often occur in upstream receptor genes such as EGFR, HER2, Flt-2, PDGFR, FMS, as well as chromosomal translocations (e.g., BCR-ABL, TEL-PDGFR) that serve to activate the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways which have been discussed as playing critical roles in cellular proliferation in this review. Hence the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways are important therapeutic targets. Both of these pathways also interact with the p53 and Wnt pathways, which also play critical roles in regulation of cell growth, aging, CICs and metastasis. Specific Raf, MEK, PI3K, Akt, mTOR and Mdm-2 inhibitors have been developed and represent promising therapies for cancer and other proliferative diseases including premature aging.

Scientists and clinicians often have an intentionally narrow view of a particular topic. For example, cancer researchers predominately consider that Raf, MEK, PI3K, Akt and mTOR inhibitors will suppress the growth of malignant cancer cells. Yet MEK and mTOR and other inhibitors may also be useful in the treatment of diseases and disorders where there is abnormal cellular proliferation. Recent reports have also demonstrated that the suppression of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways may prevent the induction of cellular senescence and aging. Clearly, this later topic, aging, greatly enhances the potential clinical uses of these targeted therapeutic drugs. In conclusion, the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways are prime therapeutic targets for diverse human diseases as well as aging.

Cancer therapy is often complex as there are relatively few cancers which proliferate in response to a single mutation preventing them from being treated with a mono-specific drug. One exception is the use of the drug Gleevec (Imatinib) for the treatment of chronic myeloid leukemia (CML). Although even with this therapeutic approach, resistance develops. Scientists and clinicians have developed newer BCR-ABL inhibitors (e.g., Dasatinib, Nilotinib, Bosutinib) which can reduce resistance which has also resulted in more through analysis and understanding of how the BCR-ABL kinase functions and resistance can arise by additional genetic mutations. These studies on BCR-ABL inhibitors have also paved the way for development of more effective inhibitors for other oncogenes.

It is possible that activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR survival pathways by additional mutations in upstream oncogenes may replace the tumor’s initial oncogene addition. This may complicate therapy as the tumor may no longer be responsive to treatment with a single inhibitor which targets the original oncogene responsible for malignant transformation as the cells now have additional downstream signalling pathways activated. In addition, the tumor cells may acquire subsequent mutations which make them resistant to inhibitors that target the original activated oncogene. Such mutations may occur in the original activated oncogene or in additional genes which are critical in anti-apoptotic survival cascades. These observations document the need for further elucidation of mechanisms of inhibitor resistance as well as the development of additional inhibitors which target either the mutated oncogene or other genes activated in the resistant cells.

The activation of multiple signalling pathways by many oncogenes illustrates the need for the targeting of more than one signalling pathway. Although one inhibitor which targets one molecule in one pathway may initially appear to be effective in inhibiting tumor cell growth, the cell may adapt and be able to survive due to the activation of an additional signalling pathway. Although the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways have distinct effects on cell proliferation, they have many common downstream targets that may be able to function in promoting survival in the absence of the corresponding functional pathway. In some cases resistance to small molecule inhibitors may be due to the activation of an additional pathway that also serves to promote survival (e.g., PIK3CA and HRAS mutations can confer resistance to MEK inhibitors and other targeted therapeutics such as Erbitux and others) [238-245].

Most cancers are more complex and often the genes and events involved are either not known or difficult to counterbalance. Chemotherapy and radiotherapy can be effective in the treatment of certain tumors, however, often cancers become resistant to these approaches, perhaps due to the emergence of CICs [203,215-217]. Thus scientists and clinicians have endeavored to develop more specific therapies that target key pathways involved in cancer growth. In this respect, the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/mTOR/Akt pathways represent key therapeutic targets as they are often dysregulated by various mutations in cancer and these cascades control the activities of many proteins.
critical for cell growth and metastasis. In fact, these pathways are already being targeted in certain cancer patients. However, usually the cancer patients being treated with inhibitors that target these cascades have diseases that often have poor prognoses. That being said, what are the pros and cons of targeting these pathways? Let us first consider the positive aspects of targeting these pathways. First, these pathways are frequently activated in human cancer, thus in many cases, targeting the cascades will suppress cell growth, in the absence of knowing the precise mutation(s) responsible for the cancer. Second, although the biochemical interactions of these pathways are quite complex, there is quite a bit of knowledge of how these pathways function. Third, some inhibitors which target key components in this pathway (e.g., rapamycin which targets mTOR) have undergone extensive evaluation in humans as they have been used to prevent allograft rejection in kidney and other transplant patients for many years. Fourth, targeting these pathways may prevent aging and cellular senescence.

Now, let us summarize some of the cons of targeting these pathways. First, an obvious problem results from these pathways controlling the expression of many downstream targets (easily in the 1000’s), thus inhibiting these pathways will be detrimental in certain cells, unless it is possible to deliver the inhibitor to specifically the cancer cell. Second, the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways cross regulate each other and other pathways including the Wnt/β-catenin pathway which is critical for many aspects of cellular growth and differentiation including the EMT. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways also regulate other pathways which have not been discussed in this manuscript. These other pathways include: the Jak/STAT, NF-κB and transforming growth factor-β (TGF-β) pathways which can be directly and indirectly regulated by ERK and Akt phosphorylation [62]. In this regards there will be a Ying-Yang effect, when one cascade is inhibited, components of the other pathway could be deregulated. Third, inhibitors that target these pathways are often cytostatic and not cytotoxic, that is somewhat logical as if these inhibitors were cytotoxic, there would be massive toxicity problems. To get around this problem, inhibitors targeting these pathways could be combined with cytotoxic chemotherapeutic drugs or radiation therapy that affects the rapidly growing cancer cell. In summary, the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR cascades are complex, interacting pathways playing key roles in normal and malignant cell growth. These pathways are frequently activated by mutations in human cancer. They represent key therapeutic targets for cancer and various other diseases as well as the prevention of aging.

ACKNOWLEDGEMENTS

This work was supported in part by grants from: Fondazione del Monte di Bologna e Ravenna, MinSan 2008 “Molecular therapy in pediatric sarcomas and leukemias against IGF-1 receptor system”, PRIN 2008 and FIRB 2010 (RBAP10447J) to AMM.

REFERENCES

1. Casar B, Pinto A, Crespo P. ERK dimmers and scaffold proteins: unexpected partners for a forgotten task. Cell Cycle. 2009; 8:1007-1013.
2. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, et al. Targeting Survival Cascades Induced by Activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008;22:708-722.
3. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R et al. Emerging Raf Inhibitors. Exp Opin Emerging Drugs 2009;14:633-648.
4. Martelli AM, Evangelisti C, Chiarini A, Cappellini A, Ogniben A, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta. 2010;1803:991-1002.
5. Korotchkinia LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging. 2010; 2:344-352.
6. Safina AF, Varga AE, Bianchi A, Zheng Q, Kunnev D, Liang P, Bakin AV. Ras alters epithelial-mesenchymal transition in response to TGFbeta by reducing actin fibers and cell-matrix adhesion. Cell Cycle. 2009;8:284-298.
7. Downward J. Targeting Ras signaling pathways in cancer therapy. Nature Reviews Cancer. 2003;3:11-22.
8. Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, Sobue K. Insulin receptor substrate-1/SHIP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells. J Biol Chem. 2004; 279:40807-40818.
9. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14:3136-145.
10. Lefloch P, Pouyssegur J, Lenormand P. Total ERK1/2 activity regulates cell proliferation. Cell Cycle. 2009;8:705-711.
11. Knizetova P, Ehrmann J, Hlobilikova A, Vancova I, Kalita O, Kolar Z, Bartek J. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle. 2008;7:2553-2561.
12. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle. 2009; 8:1168-1175.
13. Xing J, Ginty DD, Greenberg ME. Coupling of the Ras-MAPK pathway to gene activation by Rsk2, a growth factor regulated CREB kinase. Science. 1996;273:959-963.
14. Balan V, Leicht DT, Zhu J, Balan K, Kaplan A, Singh-Gupta V, Qin J, Ruan H, Comb MJ, Tzivion G. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell. 2006;17:1141-1153.
15. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell. 2005;17:215-224.
16. Brummer T, Naegle H, Reth M, Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene. 2003;22:8823-8834.
17. Catalanotti, F, Reyes G, Jesenberger V Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol. 2009;16:294-303.
18. Davis RJ. Transcriptional regulation by MAP kinases. Mol Reprod Dev. 1995;42:459-467.
19. Martelli AM, Evangelisti C, Chiarini F, McCubre JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010;1:89-103.
20. Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (p13k): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle. 2010;9:596-600.
21. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4,5-bisphosphate. Science. 1997;275:665-668.
22. Coff cr PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991;201:475-481.
23. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balp4. Curr Biol. 1997;7:261-269.
24. Lee JT, Steelman LS, Chappell WH, McCubre JA. Akt Inactivates ERK causing decreased response to chemotherapy drugs in advanced CaP cells. Cell Cycle. 2008;7:631-636.
25. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998;273:32377-32379.
26. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity. 1997;7:679-689.
27. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol. 1999;9:601-604.
28. Buitenhuis M, Coff er PJ. The role of the PI3K-PKB signaling module in regulation of hematopoiesis. Cell Cycle. 2009;8:560-566.
29. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nuñez G. Interleukin-2-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
30. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
31. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Ann Rev Pathol Mech Dis. 2009;4:127-150.
32. Diaz-Meco MT. Abu-Baker S. The Par-4/PTEN connection in tumor suppression. Cell Cycle. 2009;8:2518-2522.
33. Mahimainathan L, Choudhury GG. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem. 2004;279:15258-15268.
34. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009;8:2198-2210.
35. McCubre JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011; In Press.
36. Silva A, Yunas JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2011;118:3762-3774.
37. Gao T, Furnari F, Newton AC. PHLP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18:13-24.
38. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW, Krystal G. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proc Natl Acad Sci USA. 1996;93:1689-1693.
39. Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold A, Rohrschneider LR. p150Ship, a signal transduction molecule with inositol polypolysphosphate-5-phosphatase activity. Genes & Dev. 1996;10:1084-1095.
40. Mavaille E, Pesesse X, Kuntz C, Erneux C. Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement in SHIP-2 in negative signaling of B-cells. Biochem J. 1999;342:697-705.
41. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsett LM, Moodie S, Stokoe D. 5’-phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol. 2000;20:6860-6871.
42. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle. 2009;8:403-413.
43. Vazquez-Martín A, Oliveras-Ferraro C, Lopez-Bonet E, Menendez JA. AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle. 2009;8:3679-3683.
44. Tamburini J, Green AS, Chapanis N, Bardet V, Lacombe C, Mayeux P, Bouscary D. Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle. 2009;8:3893-3899.
45. Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem. 2009;284:12783-12791.
46. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A,
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065-3074.

47. Hresko RC, Mueckler M. mTOR: RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406-40416.

48. Gonzalez E, McGraw TE. The Akt kinases: isofrom specificity in metabolism and cancer. Cell Cycle. 2009;8:2502-2508.

49. Narasimhan SD, Mukhopadhyay A, Tissenbaum HA. InAKTivation of insulin/IGF-1 signaling by dephosphorylation. Cell Cycle. 2009;8:3878-3884.

50. Larrea MD, Wender SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle. 2009;8:3455-3461.

51. Mobasher A, Richardson S, Mobasher R, Shakhbi A, Hoyland JA. Hypoxia inducible factor 1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol. 2005;20:1327-1338.

52. Eitel JA, Bijang-Vishhehsarei K, Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE, Mayo LD. PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle. 2009;8:896-901.

53. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23:5301-5315.

54. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene Mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol. 1999;19:6195-6206.

55. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE. Akt/protein kinase B up-regulates Bcl-2 expression through a cAMP-response element-binding protein. J Biol Chem. 2000;275:10761-10766.

56. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunta, J, Sonenberg N, Blenis J. RAS/ERK signaling promotes sitespecific ribosomal protein S6 phosphorylation via RSK and stimulates Cap-dependent translation. J Biol Chem. 2007;282:14056-14064.

57. Shahbazian D, Roux PP, Muelet V, Cohen MS, Raught B, Taunta J, Hershey JB, Blenis J, Pende M, Sonenberg N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006;25:2781-2791.

58. Datta SR, Dudek, H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.

59. Fletcher JJ, Huang DC. Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle. 2008;7:39-44.

60. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 2000;10:1201-1204.

61. Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem. 2006;281:818-823.

62. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milrella M, Tafuri A, Lunghi P, Bonati A, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways to leukemia. Leukemia. 2008;22:686-707.

63. De La O JP, Murtuza LC. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. Cell Cycle. 2009;8:1860-1864.

64. Liu Y, Dean DC. Tumor initiation via loss of cell contact inhibition versus Ras mutation: do all roads lead to EMT? Cell Cycle. 2010;9:897-900.

65. Goel VK, Laser AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in Braf, Nras and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126:154-160.

66. Dahl C, Guidberg P. The genome and epigenome of malignant melanoma. APMIS. 2007;115:1161-1176.

67. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107:3847-3853.

68. Wang S, Koromilas AE. Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTase expression with implications in the transcriptional signature of Ras transformed cells. Cell Cycle. 2009;8:2070-2079.

69. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinna I, Shimazaki C, Akiyama H, Saito K, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.

70. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutations of the Braf gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52:706-712.

71. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle. 2009;8:731-735.

72. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the Braf gene in human cancer. Nature. 2002;417:949-954.

73. Libra L, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travalii S, McCubrey JA. et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle. 2005;4:1382-1384.

74. Fransé K, Klintenäs M, Osterström A, Dimberg J, Monstein HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527-533.

75. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-867.

76. Buscà R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, Ortonne JP, Ballotti R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 2000;19:2900-2910.

77. Rushworth LK, Hindley AD, O'Neil E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol. 2006;26:2262-2272.

78. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate CRAF through distinct mechanisms involving heterodimerization. Mol Cell. 2005;20:963-969.
DA. BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle. 2009;8:1402-1408.

80. Zebisch A, Staber PB, Delavari A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 2006;66:3401-3408.

81. Zebisch A, Haller M, Hiden K, Goebel T, Hoeft G, Troppmair J, Sill H. Loss of Raf kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with c-RAF germ-line mutations. Leukemia. 2009;23:1049-1053.

82. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006;311:1287-1290.

83. Nystrom A-M, Ekvall S, Berglund E, Bjorqvist M, Braaten G, Duchen K, Enell H Holmberg E, Holmund U, Olsson-Engman M Anneren G, Bondeson M-L. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J Med Genet. 2008;45:500-506.

84. Murugan AK, Dong J, Xie J, Xing M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 2009;8:2122-2124.

85. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.

86. Montalto G, Cerullo M, Giannirapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13-20.

87. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)–MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.

88. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27:951-958.

89. Taninuma S, Chatani Y, Hoshino R, Sato M, Watanabe S, Kataoka T, Nakamura T, Kohno M. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene. 1998;17:57-65.

90. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, Matsuda Y, Nomoto M, Aoyagi Y. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 2004;24:432-436.

91. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitously activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117–1128.

92. Feng CW, Chua MS, McKee AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR. Sprotty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006;66:2048–2058.

93. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, Ogata H, Yano H, et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 2006;25:6056–6066.

94. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology. 2006;131:1208–1217.

95. Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia. 2006;8:1–8.

96. Galle PR. Sorafenib in advanced hepatocellular carcinoma.-we have won a battle but not the war. J Hepatology. 2008;49:871-873.

97. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10:569–573.

98. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/akt, and ERK signaling is involved in lepin-mediated invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497-2507.

99. Schmitz KJ, Wohlschlager J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cincinnati VR, Schmid KW, Baba HA. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48:83-90.

100. Benn J, Schneider, RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA. 1994;91:10350–10354.

101. Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK, Cho H. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res. 2004;2:159–169.

102. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/akt pathways: involvement of invasive potential. FASEB J. 2004;18:1123–1125.

103. Niepmann M. Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle. 2009;8:1473–1477, 2009.

104. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8:3831–3837.

105. Wang X, Meng X, Sun X, Liu M, Gao S, Zhao J, Pei F, Yu H. Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle. 2009;8:1567–1570.

106. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.

107. Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle. 2008;7:1151-1156.

108. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24:1477-1480.

109. Shatyesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C,

www.impactaging.com
Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99-102.

110. Ligresti G, Milletello L, Steelman LS, Cavallaro A, Basile F, Nicolleti F, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in human solid tumors. Cell Cycle. 2009;8:1352-1358.

111. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007;117:2713-2722.

112. Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion Ther Targets. 2004;8:537-550.

113. Rhei K, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997;57:3657-3659.

114. Singh B, Ittmann MM, Krolewski JJ. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Can. 1998;21:166-171.

115. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128:141-156.

116. Kappes H, Goemann C, Bamberger AM, Lönning T, Milde-Langosch K. PTEN expression in breast and endometrial cancer: correlation with steroid hormone receptor status. Pathobiology. 2003;69:136-142.

117. Suzuki A, Nakano T, Mak TW, Sasaki T. Portrait of PTEN: messages from mutant mice. Cancer Sci. 2008;99:209-213.

118. Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, Chen CJ, Lee PH, Peacocke M, Santella RM, Tsou HC. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene. 1999;18:3181-3185.

119. Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, Perng Li, Wang JC, Tsai M, Chang CP. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. Cancer Invest. 2000;18:123-129.

120. Kawamura N, Nagai H, Bando K, Koyama M, Matsumoto S, Tairji T, Onda M, Fujimoto J, Ueki T, Konishi N, Shiba T, Eimi M. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res. 1999;90:413-418.

121. Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh M, Sakon M, Nishisho I, Monden M. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res. 2000;91:287-292.

122. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res. 2007;37:389-396.

123. Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno H, Tsuichiya M, Nagasue N. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 2002;100:152-157.

124. Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, Tai MH. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep. 2007;18:1417-1426.

125. Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 2003;63:3453-3458.

126. Kang-Park S, Im JH, Lee JH, Lee YI. PTEN modulates hepatitis B virus X protein induced survival signaling in Chang liver cells. Virus Res. 2006;122:53-60.

127. Dhomn N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15:294-303.

128. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Rosenberg M, Braff(V600E) cooperates with PTEN loss to induce metastatic melanoma. Nat Genet. 2009;41:544-552.

129. Butler MP, Wang SI, Chaganti RS, Parsons R, Dalla-Favera R. Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer. 1999;24:322-327.

130. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood. 1998;92:3410-3415.

131. Uddin S, Hussain A, Al Hussein K, Platanias LC, Bhatia KG. Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun. 2004;320:932-938.

132. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13:1203-1210.

133. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle. 2008;7:965-970.

134. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, España P, Bonilla F. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004;41:117-124.

135. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology. 2004;68:398-404.

136. Yang H, Kong W, Zhao JJ, O'Donnell JD, Wang J. MicroRNA expression profiling in human ovarian cancer: miR-274 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425-433.

137. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T, Akao Y, et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia. 2003;17:1-8.

138. Metzner A, Horstmann MA, Fehse B, Ortmeyer G, Niemeyer CM, Stocking C, Mayr GW, Jücker M. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRA52 or PTPN11 mutations. Gene Ther. 2007;14:699-703.

139. Cheng JG, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 1992;89:9267-9271.

140. Carpente JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins
CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlir M, Lin A, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448:439-444.

141. Stemke-Hale K, Gonzalez-Angelo M, Luhch A Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, et al. An integrative genomic and proteomic analysis of PI3KCA, PTEN and Akt mutations in breast cancer. Cancer Res. 2008;68:6084-6091.

142. Bellacosa A, DeFeo D, Godwin AK, Bell DW, Cheng JQ, Altmare DA, Wan M, Dubau L, Scambia G, Masculillo V, Ferrandina G, Benedetti Panici P, et al. Molecular alterations of the Akt oncogene in breast cancer. Int J Cancer. 1995;64:280-285.

143. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, DENG W, Prieto VG, Lazar AJ, Gersh wrinkles JE, Mills GB. A novel Akt3 mutation in melanoma tumour cells and cell lines. Brit J Cancer. 2008;99:1265-1268.

144. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-158.

145. Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 up-regulated modifier of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis and patient survival. Cancer Res. 2006;66:9221-9226.

146. Slipicevic A, Holm R, Nguyen MTP, Behler PJ, Davidson B, Flerenes VA. Expression of activated Akt and PTEN in malignant melanomas: Relationship with clinical outcome. Am J Clin Pathol. 2005;124:528-536.

147. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR. Frequent activation of Akt in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25:2053-2059.

148. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson DE, Patel D, Jones JL, O’Byrne KJ. Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:2930-2936.

149. Tanno S, Tanno S, Mitsuuchi Y, Altmare DA, Xiao GH, Testa JR. Akt activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001;61:589-593.

150. St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kB and IkB pathways. Mol Cancer. 2004;3:7.

151. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol. 2006;34:1183-1191.

152. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19:586-594.

153. Ricciardi MR, McQueen T, Chism D, Millela M, Estey E, Kaldjian J, Sebolt-Leopold J, Konopleva M, Andreiff M. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19:1543-1549.

154. McCubrey JA, Millela M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Bonati A, Cervello M, Lee JT, Steelman LS. Targeting the Raf/MEK/ERK pathway with small molecule inhibitors. Current Opinion Investigational Drugs. 2008;9:614-630.

155. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Millela M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicolletti F, et al. Emerging MEK Inhibitors. Exp Opin Emerging Drugs. 2010;15:203-223.

156. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929-1940.

157. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem. 2001;276:16969-16977.

158. Mannová P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol. 2005;79:8742-8749.

159. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009;28:305-316.

160. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 2003;20:265-273.

161. Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res. 2000;20:1343-1351.

162. Galmozzi E, Casalini P, Iorio MV, Casati B, Olgiati C, Menard S. HER2 signaling enhances 5’UTR-mediated translation of c-Myc mRNA. J Cell Physiol. 2004;200:82-88.

163. Kodar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle. 2010;9:1722-1728.

164. Gera JF, Mellinghoff IK, Shi Y, Retti MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004;279:2737-2746.

165. Chung J, Bachelier RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol. 2002;158:165-174.

166. Dobrjnak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6:1891-1895.

167. Dunsbruir WD, Gillette CE, Meyer LC, Young MP, Corbishley C, Eeles RA, Kirby RS. Molecular markers for predicting prostate cancer stage and survival. BJU Int. 2000;6:869-878.

168. Gallant P, Steiger D. Myc’s secret life without Max. Cell Cycle. 2008;9:3848-3853.

169. Hydbring P, Larsson LG. Cdk2: a key regulator of the senescence control function of Myc. Aging. 2010;2:244-250.

170. Jin J, Wang GL, Timchenko L, Timchenko NA. GSK3beta and aging liver. Aging. 2009;1:582-585.

171. Gan B, DePinho RA. mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle. 2009;8:1003-1006.

172. Lluis F, Cosma MP. Somatic cell reprogramming control: signaling pathway modulation versus transcription factor activities. Cell Cycle. 2009;8:1138-1144.

173. Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PSK6 and SIGMA1B genes. Cancer Res. 2000;60:5371-5375
174. Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252-1259.

175. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyer CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314-10319.

176. Podosypina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/- mice. Proc Natl Acad Sci USA. 2001;98:10320-10325.

177. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem. 2007;282:3571-3583.

178. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008;118:3051-3064.

179. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA. 2010;107:9660-9664.

180. Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sishida G, Huang G, Di Giandomenico S, Koff A, Nimer SD. The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle. 2009;8:3120-3124.

181. Jung-Hynes B, Ahmad N. Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle. 2009;8:1478-1483.

182. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feed back loop. Cell Cycle. 2009;8:712-715.

183. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle. 2010;9:472-478.

184. Wang B, Xiao Z, Ko HL, Ren EC. The p53 response element and transcriptional repression. Cell Cycle. 2010;9:870-879.

185. O’Prey J, Crighton D, Martin AG, Vosden KH, Fearnhead HO, Ryan KM. p53-mediated induction of Noxa and p53AIP1 requires NfkappaB. Cell Cycle. 2010;9:947-952.

186. Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ. YPEL3, a p53-regulated gene that induces cellular senescence. Cancer Res. 2010;70:3566-3575.

187. Lane DP, Cheok CF, Brown A, Madhumalar A, Ghadessy FJ, Verma C. Mdm2 and p53 are highly conserved from placozoans to man. Cell. 2010;9:540-547.

188. Ho L, Alman B. Protecting the hedgerow: p53 and hedgehog pathway interactions. Cell Cycle. 2010;9:506-511.

189. Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedstrom E, Kawiak A. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle. 2010;9:720-728.

190. Galluzzo L, Morselli E, Kepp O, Maiuri MC, Kroemer G. Defective autophagy control by the p53 rheostat in cancer. Cell Cycle. 2010;9:250-255.

191. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Pik3r2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle. 2009;8:4168-4175.

192. Mancini F, Moretti F. Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway. Cell Cycle. 2009;8:3854-3849.

193. Kim DH, Rho K, Kim S. A theoretical model for p53 dynamics: identifying optimal therapeutic strategy for its activation and stabilization. Cell Cycle. 2009;8:3707-3716.

194. Jain AK, Barton MC. Regulation of p53: TRIM24 enters the RING. Cell Cycle. 2009;8:3668-3674.

195. McCubrey JA, Abrams SL, Ligresti G, Misaghiyan N, Wong ET, Baseeck J, Troppmann J, Libra N, Nicoletti F, Molton S, McMahon M, Evangelisti C, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia. 2008;2:2080-2090.

196. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-1284.

197. McCubrey J, LaHair M, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathway. Antioxidants & Redox Signaling. 2006;8:1745-1748.

198. Franklin R, Rodriguez-Mora O, La Hair M, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxidants & Redox Signaling. 2006;8:1807-1817.

199. Brauer PM, Tyner AL. RAking in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle. 2009;8:2728-2732.

200. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle. 2010;9:487-497.

201. Lal MA, Bae D, Camilli TC, Patierno SR, Ceryak S. AKT1 mediates bypass of the G1/S checkpoint after genotoxic stress in normal human cells. Cell Cycle. 2009;8:1589-1602.

202. Zhang H. Skip the nucleus, AKT drives Skp2 and FOXO1 to the same place? Cell Cycle. 2010;9:868-869.

203. Misaghiyan N, Ligresti G, Steelman LS, Bertrand FE, Baseeck J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic stem cell – the holy grail of leukemia therapy. Leukemia. 2009;23:25-42.

204. Yilmaz NH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. PTEN-dependence distinguishes haematopoietic stem cells from leukemia-initiating cells. Nature. 2006;441:475-478.

205. Zhou J, Wulkuhle, H, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA. 2007;104:16158-16163.

206. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutsch J, Clouthier SG, Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/j-catenin signaling. PLOS Biology. 2009;7: e1000121.

207. Yim EK, Siwko S, Lin SY. Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle. 2009;8:2360-2364.

208. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle. 2009;8:731-735.

209. Saudemont A, Colucci F. PI3K signaling in lymphocyte migration. Cell Cycle. 2009;8:3307-3310.
210. Sabisz M, Skladonowski A. Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle. 2009;8:3208-3217.

211. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3243-3250.

212. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8:3274-3284.

213. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749-1758.

214. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672-679.

215. McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair M, Ferland RA, Steelman LS. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Advances in Enzyme Regulation. 2010;50:285-307.

216. McCubrey JA, Chappell WH, Abrams SL, Franklin RA, Long JM, Sattler JA, Kempf CR, Laulder P, Steelman LS. Targeting the cancer initiating cells: the Achilles’ heel of cancer. Advances in Enzyme Regulation. 2011;51: In Press.

217. Kandouz M, Haidara K, Zhao J, Brisson ML. Batist G. The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. Cell Cycle. 2010;9:398-407.

218. Garinis GA, Schumacher B. Transcription-blocking DNA damage in aging and longevity. Cell Cycle. 2009;8:2134-2135.

219. Bazarov AV, Hines WC, Mukhopadhyay R, Beliveau A, Meldoyev S, Zaslavsky Y, Yaswen P. Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes. Cell Cycle. 2009;8:3373-3378.

220. Mele DA, Bista P, Baez DV, Huber BT. Dipeptidyl-peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle. 2009;8:2425-2434.

221. Acquaviva C, Chevrier V, Chauvin JP, Fournier G, Birnbaum D, Rosnet O. The centosomal FOP protein is required for cell cycle progression and survival. Cell Cycle. 2009;8:1217-1227.

222. Jin J, Wang GL, Salisbury E, Timchenko L, Timchenko NA. GSK3beta-cyclin D3-CUGBP1-eIF2 pathway in aging and in myotonic dystrophy. Cell Cycle. 2009;8:2356-2359.

223. Gems D, Doenan R. Antioxidant defense and aging in C. elegans: is the oxidative damage theory of aging wrong? Cell Cycle. 2009;8:1681-1687.

224. Perucca P, Cazzalini O, Madine M, Savio M, Laskey RA, Vannini V, Prosperi E, Stivala LA. Loss of p21 CDKN1A impairs entry to quiescence and activates a DNA damage response in normal fibroblasts induced to quiescence. Cell Cycle. 2009;8:105-114.

225. Riffell JL, Zimmerman C, Knong A, McHardy LM, Roberg M. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle. 2009;8:3025-3038.

226. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle. 2009;8:731-735.

227. Zuzi A, Castellano-Esteve D, Ayte J, Hidalgo E. Living on the edge: stress and activation of stress responses promote lifespan extension. Aging. 2010;2:231-237.

228. Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle. 2010 Aug 15;9(16):3151-3156.

229. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008;7:1020-1035.

230. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle. 2009;8:1901-1904.

231. Demidenko ZN, Shutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle. 2009;8:1896-1900.

232. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8:1888-1895.

233. Blagosklonny MV. Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic declaration. Cell Cycle. 2009;8:1883-1887.

234. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8:909-915.

235. Guenther GG, Gdinger AL. A new take on ceramicide: starve cells by cutting off the nutrient supply. Cell Cycle. 2009;8:1122-1126.

236. Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV. Cellular quiescence caused by the Mdm-2 inhibitor nutlin-3A. Cell Cycle. 2009;8:3777-3781.

237. Shen J, Curtis C, Tavare S, Tower J. A screen of apoptosis and senescence regulatory genes for life span effects when over-expressed in Drosophila. Aging. 2009;1:191-211.

238. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009;69: 4286-4293.

239. Hoeflisch KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnosome E, Truong T, Zhou W, Berry L, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase in basal-like breast cancer models. Clin Cancer Res. 2009;15: 4649-4664.

240. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924-5930.

241. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2009;15:1133-1139.

242. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
243. Lièvre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010; 29:3033-3043.

244. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Sawai A, Janakiraman M, Taylor BS, Pao W, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008; 68:9375-9383.

245. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res. 2010; 16:3329-3334.